var title_f20_35_21040="Mitosis";
var content_f20_35_21040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 615px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21040=[""].join("\n");
var outline_f20_35_21040=null;
var title_f20_35_21041="Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)";
var content_f20_35_21041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1831178159\">",
"      <span class=\"h1\">",
"       What is amyotrophic lateral sclerosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is a disease that damages the nerves that control muscles. This causes the muscles to weaken. The muscles slowly stop working, leaving the person unable to move (called &ldquo;paralysis&rdquo;). Over time, the disease gets worse and leads to death. ALS is also known as &ldquo;Lou Gehrig&rsquo;s disease,&rdquo; after the famous baseball player who died of the disease.",
"     </p>",
"     <p>",
"      Most people who get ALS live only a few years after their symptoms begin. There is no cure for ALS, but doctors can treat the symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1831178174\">",
"      <span class=\"h1\">",
"       What are the symptoms of ALS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weak arm or leg muscles, usually starting in one arm or leg and later spreading to other parts of the body",
"       </li>",
"       <li>",
"        Trouble speaking or swallowing",
"       </li>",
"       <li>",
"        Slow, stiff, or awkward movements",
"       </li>",
"       <li>",
"        Muscle twitches and spasms",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a person gets weak muscles in the hands or arms, he or she might have problems with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using buttons or zippers",
"       </li>",
"       <li>",
"        Handling coins or other small things",
"       </li>",
"       <li>",
"        Writing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a person gets weak muscles in the legs or feet, he or she might have problems with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Walking and turning",
"       </li>",
"       <li>",
"        Balance",
"       </li>",
"       <li>",
"        Climbing stairs",
"       </li>",
"       <li>",
"        Standing up from a chair or the floor",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these symptoms happen, the person might have other problems, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling like the legs are &ldquo;heavy&rdquo;",
"       </li>",
"       <li>",
"        Dragging the front of the foot on the ground when walking",
"       </li>",
"       <li>",
"        Tripping or falling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If a person gets weak muscles in the head, neck, or chest, he or she might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a stiff jaw and a hard time opening the mouth",
"       </li>",
"       <li>",
"        Clench and bite",
"       </li>",
"       <li>",
"        Have trouble swallowing",
"       </li>",
"       <li>",
"        Have trouble moving the mouth and tongue to speak clearly",
"       </li>",
"       <li>",
"        Drool",
"       </li>",
"       <li>",
"        Not be able to fully close the eyes",
"       </li>",
"       <li>",
"        Have trouble holding up the head due to weak neck muscles",
"       </li>",
"       <li>",
"        Have trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with ALS have mood changes. They also might laugh, cry, or yawn at times when it doesn&rsquo;t make sense to do those things. In a few people, ALS affects the mind and causes problems with thinking clearly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1831178189\">",
"      <span class=\"h1\">",
"       Are there tests for ALS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor might be able to tell if you have it by learning about your symptoms and doing an exam. But your doctor will probably do tests, such as electromyography (also called &ldquo;EMG) to check how well your nerves are working. Other tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        MRI &ndash; This is an imaging test that takes pictures of your brain and backbone (also called the &ldquo;spine&rdquo;).",
"       </li>",
"       <li>",
"        Blood and urine tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might need other tests to check that a different problem isn&rsquo;t causing your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1831178204\">",
"      <span class=\"h1\">",
"       How is ALS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments for ALS include a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?32/21/33108?source=see_link\">",
"       riluzole",
"      </a>",
"      (brand name: Rilutek&reg;). This medicine works by slowing down the progress of the disease a little bit. It can help people live a few months longer.",
"     </p>",
"     <p>",
"      Other treatments help people cope with the symptoms of ALS. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Breathing support &ndash; For this treatment, you wear a tight-fitting mask on your face or nose. Air and oxygen flow through the mask to help you breathe.",
"       </li>",
"       <li>",
"        Feeding tube &ndash; This is a small, flexible tube that goes through the skin over your belly into your stomach. You can then get special liquid food and fluids through the tube directly into your stomach.",
"       </li>",
"       <li>",
"        Devices to help with walking and talking, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A cane, crutches, or motorized wheelchair",
"       </li>",
"       <li>",
"        A special computer that &ldquo;talks&rdquo; for you. You can control the computer with hand or eye movements.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat muscle spasms and weakness, drooling, sleep problems, pain, and depression",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/35/21041?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86016 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21041=[""].join("\n");
var outline_f20_35_21041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1831178159\">",
"      What is amyotrophic lateral sclerosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1831178174\">",
"      What are the symptoms of ALS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1831178189\">",
"      Are there tests for ALS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1831178204\">",
"      How is ALS treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21042="Atypical nevus - fried egg";
var content_f20_35_21042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atypical nevus with a \"fried egg\" appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21042=[""].join("\n");
var outline_f20_35_21042=null;
var title_f20_35_21043="MRI cortical glioneuronal hamartomas";
var content_f20_35_21043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain magnetic resonance imaging of cortical glioneuronal hamartomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluid-attenuated inversion recovery image demonstrating multiple areas of high signal corresponding to cortical glioneuronal hamartomas, also known as tubers (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Crino PB, Henske EP. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 1999; 53:1384. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21043=[""].join("\n");
var outline_f20_35_21043=null;
var title_f20_35_21044="Tioconazole: Patient drug information";
var content_f20_35_21044=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tioconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/6/34914?source=see_link\">",
"     see \"Tioconazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      1-Day&trade; [OTC];",
"     </li>",
"     <li>",
"      Vagistat&reg;-1 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tioconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have belly pain, fever, or bad-smelling discharge. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use ointment vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11097 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21044=[""].join("\n");
var outline_f20_35_21044=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228171\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018828\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018827\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018832\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018833\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018835\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018830\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018831\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018836\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018837\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/6/34914?source=related_link\">",
"      Tioconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21045="Characteristics of the hepatitis B virus and pathogenesis of infection";
var content_f20_35_21045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Characteristics of the hepatitis B virus and pathogenesis of infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21045/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/35/21045/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) infection is a global public health problem. The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical hepatitis to anicteric hepatitis, icteric hepatitis, and fulminant hepatitis; during the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The clinical outcome of HBV infection depends upon the age at infection, the level of HBV replication, and the immune status of the host. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the characteristics of the hepatitis B virus and the pathogenesis of HBV-related liver disease. The immune response to HBV contributes to the hepatic injury, helps control the infection, and provides the means for establishing the serologic diagnosis of HBV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF THE VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus belongs to the family of hepadnaviruses, which include duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. The complete virion or Dane particle is 42 nm in diameter. It consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An envelope composed of viral-encoded proteins and host-derived lipid components",
"     </li>",
"     <li>",
"      A core particle made up of the nucleocapsid protein, the viral genome, and the polymerase protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HBV also produces 22 nm subviral particles in the form of filaments and spheres that are composed of envelope proteins only. These subviral particles do not contain the HBV genome and are therefore noninfectious [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genome of HBV is a relaxed circular, partially double stranded DNA of approximately 3200 base pairs in length [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"     1",
"    </a>",
"    ]. There are four partially overlapping open reading frames (ORFs) encoding the envelope",
"    <span class=\"nowrap\">",
"     (pre-S/S),",
"    </span>",
"    core",
"    <span class=\"nowrap\">",
"     (precore/core),",
"    </span>",
"    polymerase, and X proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     pre-S/S",
"    </span>",
"    ORF consists of three in-phase start codons and a common stop codon that divides the gene into pre-S1, pre-S2 and S regions encoding the large (L), middle (M), and small (S) envelope proteins, respectively (",
"    <a class=\"graphic graphic_figure graphicRef74116 \" href=\"UTD.htm?42/35/43580\">",
"     figure 1",
"    </a>",
"    ). The M and S envelope proteins are found in all forms of viral and subviral particles while the L envelope proteins are predominantly found in complete virions.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     precore/core",
"    </span>",
"    ORF consists of two in-phase start codons (",
"    <a class=\"graphic graphic_figure graphicRef61295 \" href=\"UTD.htm?8/2/8238\">",
"     figure 2",
"    </a>",
"    ). Translation from the precore start codon produces a precore polypeptide which is posttranslationally modified into a soluble protein, the hepatitis B e antigen (HBeAg). Translation from the second start codon produces the core protein (HBcAg).",
"   </p>",
"   <p>",
"    The polymerase ORF overlaps with the core, envelope, and X ORFs. The polymerase protein consists of a protein primer, a spacer, a reverse",
"    <span class=\"nowrap\">",
"     transcriptase/DNA",
"    </span>",
"    polymerase, and an RNAase H domain.",
"   </p>",
"   <p>",
"    The X protein is not required for the replication of the virus. It is a potent transcriptional transactivator of many promoters including HBV and cellular oncogenes. The HBx protein has been implicated in hepatocarcinogenesis.",
"   </p>",
"   <p>",
"    Two major transcripts (3.5 and 2.1 kb) are made [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"     1",
"    </a>",
"    ]. The 3.5 kb RNA has heterogeneous 5'-ends:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The precore mRNA is slightly longer and is initiated upstream of the precore start codon. It is translated into the precore polypeptide, which is then processed at both the N and C terminal ends to a smaller protein, the HBeAg (",
"      <a class=\"graphic graphic_figure graphicRef61295 \" href=\"UTD.htm?8/2/8238\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The pregenomic RNA is initiated within the precore region. It serves as a replicative intermediate and is reverse transcribed into HBV DNA (",
"      <a class=\"graphic graphic_figure graphicRef61295 \" href=\"UTD.htm?8/2/8238\">",
"       figure 2",
"      </a>",
"      ). In addition, it functions as a messenger RNA for translation into the nucleocapsid and polymerase proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2.1 kb RNA is initiated within the pre-S1 region and is translated into middle and small S proteins (",
"    <a class=\"graphic graphic_figure graphicRef74116 \" href=\"UTD.htm?42/35/43580\">",
"     figure 1",
"    </a>",
"    ). There are also at least two minor transcripts: the 2.4 kb RNA, which is translated into the large S protein (",
"    <a class=\"graphic graphic_figure graphicRef74116 \" href=\"UTD.htm?42/35/43580\">",
"     figure 1",
"    </a>",
"    ), and a smaller RNA, which is translated into the X protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV has been classified into eight genotypes (A to H) based upon an inter-group divergence of 8 percent or more in the complete nucleotide sequence. HBV genotypes have been associated with a risk of HCC development and a response to interferon therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Replication cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The replication cycle of HBV begins with attachment of the virion to the hepatocyte membrane (",
"    <a class=\"graphic graphic_figure graphicRef59125 \" href=\"UTD.htm?4/54/4960\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"     1",
"    </a>",
"    ]. The exact mechanisms of virus attachment are not clear but are thought to be mediated through the pre-S1 region of the virion envelope. The virion is uncoated in the hepatocyte cytoplasm and the viral genome enters the hepatocyte nucleus.",
"   </p>",
"   <p>",
"    Inside the hepatocyte nucleus, synthesis of the plus strand HBV DNA is completed and the viral genome is converted into a covalently closed circular DNA (ccc DNA).",
"   </p>",
"   <p>",
"    The HBV genome replicates by reverse transcription via an RNA intermediate, the pregenomic RNA. The pregenomic RNA, nucleocapsid, and polymerase proteins are encapsidated in the virus core particle inside which reverse transcription takes place. The pregenomic RNA is the only RNA transcript which is encapsidated. Encapsidation is regulated by the pregenome encapsidation sequence (e) which is located in the precore and proximal core region.",
"   </p>",
"   <p>",
"    A new minus strand HBV DNA is produced followed by the synthesis of a new plus strand HBV DNA. Nucleocapsids with the partially double stranded HBV DNA can reenter the hepatocyte nucleus to produce more ccc DNA or be secreted as complete virions after coating with envelope proteins. The ccc DNA appears to have a long half-life and is very resistant to antiviral therapy, accounting for the difficulty in achieving virus clearance during treatment of chronic hepatitis B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HBV-related liver disease is largely due to immune-mediated mechanisms. In some circumstances, HBV can cause direct cytotoxic liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immune-mediated liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV-related liver disease is generally thought to be related to cytotoxic T cell-mediated lysis of infected hepatocytes. The following observations are consistent with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Events associated with immune clearance, such as spontaneous or interferon-induced HBeAg seroconversion, are often accompanied by exacerbations of liver disease as evidenced by an elevated serum ALT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with chronic hepatitis B who clear HBeAg have more vigorous CTL responses to HBV antigens than those who remained HBeAg positive [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fulminant hepatitis B is believed to be due to massive immune-mediated lysis of infected hepatocytes. This explains why many patients with fulminant hepatitis B have no evidence of HBV replication at presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to promoting hepatic injury, both the T cell and antibody responses to HBV help to control the infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .) In one study, for example, HBV-specific cytotoxic T cells from patients studied up to 23 years after clinical and serologic recovery expressed activation markers indicating recent contact with HBV antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/5\">",
"     5",
"    </a>",
"    ]. This observation suggests that complete eradication of HBV rarely occurs after recovery from acute hepatitis and that traces of virus can maintain the T cell response for decades following clinical recovery, which in turn keeps the virus under control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of five patients who were identified during the incubation phase of acute HBV infection, NK cell activation was detected first followed by HBV-specific T cell response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/7\">",
"     7",
"    </a>",
"    ]. The presence of HBV-specific CD8+ and CD4+ cells during the incubation phase suggests that these cells play an important role in the control of infection and in the initiation of events that lead to liver damage. Maximal reduction in HBV-DNA levels occurred prior to peak increase in serum ALT levels, suggesting that viral control is mediated through noncytolytic as well as cytolytic mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Direct cytotoxic liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV is generally not a cytopathic virus. In most patients with chronic hepatitis B, for example, there is no direct correlation between viral load and the severity of liver disease. This is particularly true during the early phase of perinatally acquired HBV infection in which there is high serum HBV DNA but normal serum ALT concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, direct cytopathic liver injury can occur when the viral load is very high as in fibrosing cholestatic hepatitis, an unusual form of liver disease seen in some patients with recurrent hepatitis B following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Role of viral variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in all regions of HBV have been found in patients with chronic HBV infection. Some of these mutations, such as the precore stop codon mutation, have been incriminated in causing more severe liver disease (",
"    <a class=\"graphic graphic_figure graphicRef61295 \" href=\"UTD.htm?8/2/8238\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, these variants have also been found in asymptomatic carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/13\">",
"     13",
"    </a>",
"    ], suggesting that the mutations alone are not necessarily pathogenic. Nevertheless, HBV mutations can potentially modulate the severity of liver disease by altering the level of HBV replication or the expression of immunogenic epitopes. Some variants, for example, do not make HBeAg. Nevertheless, the virus can continue to replicate (as determined by the presence of HBV DNA in serum and elevated serum ALT) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and, in the case of four surgeons, transmit the infection to others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=see_link\">",
"     \"Clinical significance and molecular characteristics of common hepatitis B virus variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Development of chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who progress to chronic HBV infection have weak and limited immune response to HBV epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/4,17-20\">",
"     4,17-20",
"    </a>",
"    ]. Some studies also found relatively increased activation of the host's immunosuppressive mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21045/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25974980\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genome of hepatitis B virus (HBV) is a relaxed circular, partially double stranded DNA of approximately 3200 base pairs in length and 42 nm in diameter. It belongs to the family of hepadnaviruses, which include the duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Characteristics of the virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HBV has been classified into eight genotypes (A to H) based upon an inter-group divergence of 8 percent or more in the complete nucleotide sequence. HBV genotypes may influence hepatocellular carcinoma risk and a response to interferon therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genotypes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"       \"Clinical significance of hepatitis B virus genotypes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pathogenesis of HBV-related liver disease is largely due to immune-mediated mechanisms. In some circumstances, HBV can cause direct cytotoxic liver injury. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/1\">",
"      Scaglioni PP, Melegari M, Wands JR. Recent advances in the molecular biology of hepatitis B virus. Baillieres Clin Gastroenterol 1996; 10:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/2\">",
"      Liaw YF, Pao CC, Chu CM, et al. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/3\">",
"      Perrillo RP. The management of chronic hepatitis B. Am J Med 1994; 96:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/4\">",
"      Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/5\">",
"      Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/6\">",
"      Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/7\">",
"      Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/8\">",
"      Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/9\">",
"      Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/10\">",
"      Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/11\">",
"      Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/12\">",
"      Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/13\">",
"      Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994; 19:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/14\">",
"      Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/15\">",
"      Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/16\">",
"      Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. The Incident Investigation Teams and others. N Engl J Med 1997; 336:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/17\">",
"      Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/18\">",
"      Rehermann B, Chang KM, McHutchinson J, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70:7092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/19\">",
"      Penna A, Artini M, Cavalli A, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/20\">",
"      Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21045/abstract/21\">",
"      Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41:771.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3631 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21045=[""].join("\n");
var outline_f20_35_21045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25974980\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHARACTERISTICS OF THE VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Replication cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immune-mediated liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Direct cytotoxic liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Role of viral variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Development of chronic infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25974980\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3631|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/35/43580\" title=\"figure 1\">",
"      HBV pre S-S ORF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/2/8238\" title=\"figure 2\">",
"      HBV precore-core ORF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/54/4960\" title=\"figure 3\">",
"      HBV replication cycle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=related_link\">",
"      Clinical significance and molecular characteristics of common hepatitis B virus variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21046="Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis";
var content_f20_35_21046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21046/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/35/21046/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic onset juvenile idiopathic arthritis (formerly called Still's disease or systemic onset juvenile rheumatoid arthritis) is officially classified as a subset of juvenile idiopathic arthritis (JIA) that describes patients with intermittent fever, rash, and arthritis. It is sometimes called adult-onset Still's disease when it occurs in patients over the age of 16. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39994?source=see_link\">",
"     \"Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with systemic onset juvenile idiopathic arthritis (JIA) fall into the category of systemic onset arthritis in the new proposed classification of the childhood arthritides. Children with this illness comprise between 10 and 20 percent of all cases of JIA. However, data suggest that this illness is an autoinflammatory condition unrelated to the other diseases categorized as JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This form of JIA may be the most difficult to diagnose and treat for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthritis, although necessary to establish a definitive diagnosis, may not be evident early in the course of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Affected children often appear quite ill with high spiking fevers, rashes, markedly elevated white blood cell counts, and anemia. Most such children are initially thought to have an infection or malignancy, and the correct diagnosis is only suspected after there has been no response to antibiotic therapy and malignancy has been excluded.",
"     </li>",
"     <li>",
"      Some children with this disorder are initially thought to have leukemia because of the high white blood cell counts.",
"     </li>",
"     <li>",
"      Some children who present with fever, rash, and diffuse joint pain do in fact have infections, leukemia, or other serious conditions that are not systemic onset JIA. Thus, it is essential that clinicians thoroughly exclude other conditions before making this diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with systemic onset JIA require close supervision and careful monitoring. Systemic complications, including drug reactions, macrophage activation syndrome, pericarditis, and other forms of internal organ involvement, are more common in this subtype of JIA than in any other [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of systemic onset JIA are reviewed here (",
"    <a class=\"graphic graphic_table graphicRef56224 \" href=\"UTD.htm?38/15/39164\">",
"     table 1",
"    </a>",
"    ). The management, complications, and prognosis of systemic onset JIA as well as pauciarticular and polyarticular onset JIA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the other subtypes of JIA that occur predominantly in females, systemic onset JIA affects both sexes equally. It may begin in young children during the first or second year of life, although cases are distributed throughout childhood. By definition, systemic onset JIA does not occur after the age of 16 years. A similar illness has been described in adults and is called adult-onset Still's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/4\">",
"     4",
"    </a>",
"    ]. Many of the latter patients give a history of an undiagnosed prolonged febrile illness before age 16 that might have been the initial episode of systemic onset JIA. Recurrent disease after the age of 16 is not adult-onset Still's disease, but simply a continuation of systemic onset JIA.",
"   </p>",
"   <p>",
"    Children with systemic onset JIA may present with a variety of articular and extraarticular signs and symptoms. In one large case series from a tertiary center, 136 patients were diagnosed with systemic JIA from 1990 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/5\">",
"     5",
"    </a>",
"    ]. The following manifestations at disease onset and relative frequency were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 98 percent",
"     </li>",
"     <li>",
"      Arthritis &mdash; 88 percent (8 percent with monoarthritis, 45 percent with oligoarthritis, and 47 percent with polyarthritis)",
"     </li>",
"     <li>",
"      Rash &mdash; 81 percent",
"     </li>",
"     <li>",
"      Lymphadenopathy &mdash; 31 percent",
"     </li>",
"     <li>",
"      Laboratory findings included elevated erythrocyte sedimentation rate (95 percent) and C-reactive protein (96 percent). In addition, the median white count was elevated and median hemoglobin was low. In most children, the platelet count will also be elevated. A low or even low normal platelet count suggests either a different diagnosis or the onset of macrophage activation syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Articular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthralgias are common early in the course of systemic onset JIA, but arthritis may not be prominent. When it does become apparent, any number of joints may be involved. Disease in the wrists, knees, and ankles is most typical, but the hands, hips, cervical spine, and temporomandibular joints also may be affected. Unlike the pauciarticular and polyarticular subtypes of JIA, the arthritis of systemic onset JIA may begin in the hips and may progress very rapidly, causing severe damage and dysfunction as well as loss of growth potential in younger patients. Wrist involvement is common. Diffuse and symmetrical swelling of the distal interphalangeal joints may be present and is unique to this form of arthritis in childhood.",
"   </p>",
"   <p>",
"    Micrognathia and cervical spine fusion are commonly present in children with chronic systemic onset JIA, but do not appear until after the disease has been present for months to years (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70981 \" href=\"UTD.htm?33/55/34686\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/6\">",
"     6",
"    </a>",
"    ]; these abnormalities may affect 50 percent of children with disease onset in the first decade of life. Why they occur more frequently in this subtype (compared to nonsystemic subtypes) is unknown, but highlights the suspicion that this is a separate disease entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Extraarticular manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with systemic onset JIA usually come to medical attention because of high spiking fevers. The key finding that suggests the diagnosis is the intermittent nature of the fever; the diagnosis is strongly in doubt if the patient&rsquo;s temperature does not spontaneously return to normal on a daily basis. Affected children are characteristically ill-appearing when febrile but seem to improve dramatically when their temperature is normal. These features, in addition to the lack of response to antibiotics, help to distinguish patients with systemic onset JIA from those with an infection.",
"   </p>",
"   <p>",
"    Often the diagnosis of systemic onset JIA is considered when a child is admitted to the hospital with fever unresponsive to antibiotics as an outpatient. The antibiotic regimen is typically changed on admission and the next morning the child is afebrile and looks dramatically better. At first this is attributed to the change in antibiotics, but the child with systemic onset JIA will typically develop fever and appear ill again in the afternoon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;A macular, salmon pink rash is frequently present (",
"    <a class=\"graphic graphic_picture graphicRef62959 \" href=\"UTD.htm?13/24/13711\">",
"     picture 1",
"    </a>",
"    ). The rash is brought out by heat, and often can be found in the axillae and around the waist, but may be present anywhere on the body. It is most prominent when the child is febrile. Unlike viral exanthems, which persist, the rash often fades as the temperature returns to normal, only to reappear with the next fever spike. The rash also may appear following stroking of the skin or other minor trauma (Koebner phenomenon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, the following clinical features are commonly observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatomegaly, splenomegaly, and lymphadenopathy commonly are found. This combination frequently raises suspicion of a malignancy, but lymph node biopsy shows benign reactive hyperplasia. The severity of pain may help distinguish malignancy from systemic onset JIA. Children with systemic onset JIA are uncomfortable and may have swollen joints, but they rarely cry out from pain even when their joints are manipulated. By comparison, children with leukemia or other malignancies may be exquisitely uncomfortable and often complain of pain when the shaft of a long bone is compressed (eg, mid-humerus or mid-femur) far from any articulation.",
"     </li>",
"     <li>",
"      A small pericardial effusion is often noted on echocardiogram; this is usually not clinically significant. Large pericardial effusions are rare.",
"     </li>",
"     <li>",
"      Some children with systemic onset JIA have been reported to have chronic headaches and other neurologic symptoms.",
"     </li>",
"     <li>",
"      Systemic onset JIA is normally associated with a significant elevation of the platelet count. A low or even low normal count should prompt further investigation and suggests either the onset of macrophage activation syndrome or that the diagnosis of systemic onset JIA is incorrect.",
"     </li>",
"     <li>",
"      Vasculitis, including digital infarctions and seizures, occurs rarely. Whether cases with significant vasculitic manifestations truly represent systemic onset JIA, or represent cases of systemic vasculitis with arthritis, is unclear. The presence or absence of intermittent fever may provide a basis for differentiation.",
"     </li>",
"     <li>",
"      Pulmonary manifestations include pleural effusions (commonly present during the acute phase of the illness) and diffuse interstitial pneumonitis (rare).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of systemic onset JIA is the combination of intermittent daily fevers greater than 38.5&ordm;C and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/2\">",
"     2",
"    </a>",
"    ]. The fever must be present for at least",
"    <strong>",
"     two weeks",
"    </strong>",
"    in order to make a definitive diagnosis, since many viral and other postinfectious forms of arthritis also may be associated with fever. However these infectious illnesses often lack the characteristic intermittent spiking fever pattern of systemic onset JIA. There may be a prolonged delay between the onset of fever and the development of arthritis, but a definitive diagnosis of systemic onset JIA cannot be made until arthritis is present. In the presence of a characteristic fever pattern, rash, and arthritis, a tentative diagnosis of systemic onset JIA can be made and appropriate therapy begun before two weeks have elapsed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic onset JIA is a diagnosis of exclusion, since there are no laboratory findings that are specific for the diagnosis. However, characteristic patterns of laboratory abnormalities frequently are present and suggestive of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      White blood cell counts (WBC) in the 20,000 to",
"      <span class=\"nowrap\">",
"       30,000/mm3",
"      </span>",
"      range are not uncommon, and at times they may exceed 60,000 to 80,000; granulocytes predominate.",
"     </li>",
"     <li>",
"      There is usually a marked reactive thrombocytosis and the platelet count may exceed",
"      <span class=\"nowrap\">",
"       1,000,000/mm3.",
"      </span>",
"      Thus, thrombocytopenia or even low normal platelet counts (eg, less than",
"      <span class=\"nowrap\">",
"       200,000/mm3)",
"      </span>",
"      should prompt careful evaluation for an alternative diagnosis (eg, bone marrow aspiration to exclude leukemia). A sudden rapid drop in the platelet count may herald the development of macrophage activation syndrome (MAS).",
"     </li>",
"     <li>",
"      Anemia is commonly present and often profound. It is primarily due to decreased synthesis and poor absorption of oral iron rather than increased destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/7\">",
"       7",
"      </a>",
"      ]. The anemia is often exacerbated by chronic gastrointestinal blood loss induced by NSAIDs. Thus, children with systemic onset JIA commonly become iron deficient over time, but oral iron supplementation is often ineffective until the underlying inflammatory process has been corrected. Intravenous or intramuscular iron may be required in cases of severe iron deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/8\">",
"       8",
"      </a>",
"      ]. Oral iron supplementation is often necessary once systemic onset disease begins to come under control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"       \"Treatment of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The erythrocyte sedimentation rate is typically elevated in children with systemic onset JIA and may exceed 100",
"      <span class=\"nowrap\">",
"       mm/hr;",
"      </span>",
"      normal sedimentation rates are rare when the disease is active. The level of C-reactive protein, another acute phase reactant, is usually elevated as well. The combination of a dramatic fall in the erythrocyte sedimentation rate and a dramatic fall in the platelet count may herald the onset of MAS rather than clinical improvement. Careful evaluation of children with this combination of findings is essential. A dramatic rise in the serum ferritin level or in fibrin split products (D-dimers) also strongly suggests the onset of MAS.",
"     </li>",
"     <li>",
"      Minor AST and ALT enzyme elevations, hypoalbuminemia, and increased globulin levels are often present. However, markedly elevated hepatic enzyme abnormalities, prolonged clotting times, or the appearance of fibrin split products should prompt immediate consideration of diffuse intravascular coagulation (DIC) or MAS.",
"     </li>",
"     <li>",
"      The urinalysis should be normal in children with systemic onset JIA. Although some children manifest low grade proteinuria when febrile, significant proteinuria or hematuria should not be seen. Secondary amyloidosis resulting in proteinuria that can reach the nephrotic range has been reported in the European literature, but is exceedingly rare [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/3\">",
"       3",
"      </a>",
"      ]. Thus, the presence of hematuria or significant proteinuria in combination with fever, arthritis, and rash should prompt consideration of another diagnosis, such as systemic lupus erythematosus rather than JIA. Although a positive ANA may be seen in other forms of JIA it is rare in children with systemic onset disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyarteritis nodosa may also present with fever, rash, and arthritis in this age group. Continued abdominal pain is common in polyarteritis nodosa and should prompt consideration of this illness once other causes have been excluded. Chronic abdominal pain in a child with suspected systemic onset JIA should not be ascribed to benign conditions, such as \"mesenteric adenitis\", without thorough investigation to exclude other possible diagnoses.",
"     </li>",
"     <li>",
"      Antinuclear antibodies (ANA) and rheumatoid factor (RF) rarely are seen in systemic onset JIA. Their presence should prompt consideration of alternative diagnoses. RF, for example, may be associated with Sj&ouml;gren's syndrome or the early onset of adult type RA in teenagers. Both RF and ANA may be present in children with mixed connective tissue disease (MCTD). However, these conditions rarely mimic systemic onset JIA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic onset JIA can be confused with a number of other disorders:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postinfectious arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinfectious and viral arthritis often present with fever that is not intermittent, rash that differs in appearance from that of systemic onset JIA, and transient arthritis. Parvovirus B19 is one of the most commonly confused viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/9\">",
"     9",
"    </a>",
"    ]. The mistaken diagnosis of these self-limited conditions as systemic onset JIA is in large part responsible for the incorrect notion that the latter disorder often resolves completely without aggressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1558?source=see_link\">",
"     \"Pathogenesis and diagnosis of viral arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis may follow a variety of bacterial infections. Those typically associated with fever, rash, and arthritis include neisserial and streptococcal infections. Subacute bacterial endocarditis may present with these symptoms and may be associated with a positive test for RF. These entities can usually be differentiated by their clinical picture, appropriate cultures, and the response to antibiotics.",
"   </p>",
"   <p>",
"    Reactive arthritis following enteric infection and inflammatory bowel disease may be mistakenly diagnosed as systemic onset JIA. The key differential features pointing away from a diagnosis of systemic onset JIA include gastrointestinal complaints, ocular findings, and lack of the classic salmon pink rash. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other connective tissue diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis with fever and rash also may be the presenting manifestations in systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis, sarcoidosis, neonatal onset multisystem inflammatory disease, and other connective tissue diseases. These illnesses are excluded by appropriate clinical and laboratory evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every pediatric rheumatology center reports the referral of children thought to have systemic onset JIA who were found to have leukemia, lymphoma, or other malignancies. Clinician awareness is the key to proper diagnosis. Systemic onset JIA is not associated with thrombocytopenia, lymphocytosis, neutropenia, or extreme pain. The child who cries and screams with discomfort on being touched is unlikely to have systemic onset JIA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21046/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria may have a diurnal fever pattern identical to that of systemic onset JIA and is also associated with chills, joint pains, and evidence of systemic illness. Malaria is extremely rare in the United States, but if the patient gives a history of residence in or travel to endemic areas, appropriate thick blood smears to exclude this diagnosis should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marrow infiltrative diseases, such as histiocytosis X, and inherited conditions, such as Gaucher's disease, and Hunter's and Hurler's syndromes, also may present with fever, joint pain, and rash. However, none of these illnesses manifest the laboratory findings, the fever pattern or the typical salmon pink rash of systemic onset JIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic onset juvenile idiopathic arthritis (formerly called Still's disease or systemic onset juvenile rheumatoid arthritis) is officially a subset of juvenile idiopathic arthritis (JIA) that describes patients with intermittent fever, rash, and arthritis.",
"     </li>",
"     <li>",
"      Systemic onset JIA accounts for 10 to 20 percent of all cases of JIA. It typically affects both sexes equally and may present in children as young as one year of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is the most difficult form of JIA to diagnosis because arthritis, which is necessary for the definite diagnosis, is often not evident early in the course of the disease. In addition, infection and malignancies are often considered prior to the diagnosis of systemic onset JIA in these cases because patients initially appear quite ill with high spiking fever, rash, and often have hepatomegaly or lymphadenopathy, and elevated white counts prior to the presentation of arthritis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made clinically and is based upon the presence of intermittent fever for at least two weeks and arthritis. There are no laboratory findings that are specific for the diagnosis of systemic onset JIA. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/1\">",
"      Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011; 377:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/2\">",
"      Criteria for the classification of juvenile rheumatoid arthritis. Bull Rheum Dis 1972; 23:712.",
"     </a>",
"    </li>",
"    <li>",
"     Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. In: Textbook of Pediatric Rheumatology, 4th ed, Cassidy JT, Petty RE (Eds), WB Saunders Company, Philadelphia 2001. p.218.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/4\">",
"      Cush JJ, Medsger TA Jr, Christy WC, et al. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/5\">",
"      Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/6\">",
"      Hensinger RN, DeVito PD, Ragsdale CG. Changes in the cervical spine in juvenile rheumatoid arthritis. J Bone Joint Surg Am 1986; 68:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/7\">",
"      Harvey AR, Pippard MJ, Ansell BM. Microcytic anaemia in juvenile chronic arthritis. Scand J Rheumatol 1987; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/8\">",
"      Martini A, Ravelli A, Di Fuccia G, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/9\">",
"      Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. J Pediatr 1993; 122:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21046/abstract/10\">",
"      Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999; 134:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6413 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21046=[""].join("\n");
var outline_f20_35_21046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Articular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Extraarticular manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other clinical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postinfectious arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other connective tissue diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6413|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/55/34686\" title=\"diagnostic image 1\">",
"      C spine fusion systemic JIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6413|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13711\" title=\"picture 1\">",
"      Systemic onset JIA rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6413|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/15/39164\" title=\"table 1\">",
"      Features of JIA subtypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39994?source=related_link\">",
"      Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1558?source=related_link\">",
"      Pathogenesis and diagnosis of viral arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39285?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21047="Chlorpromazine: Pediatric drug information";
var content_f20_35_21047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpromazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"    see \"Chlorpromazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20661?source=see_link\">",
"    see \"Chlorpromazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlorpromazine Hydrochloride Inj;",
"     </li>",
"     <li>",
"      Teva-Chlorpromazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neonatal abstinence syndrome (withdrawal from maternal opioid use; controls CNS and gastrointestinal symptoms):",
"     <b>",
"      Note:",
"     </b>",
"     Chlorpromazine is rarely used for neonatal abstinence syndrome due to adverse effects such as hypothermia, cerebellar dysfunction, decreased seizure threshold, and eosinophilia; other agents are preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Initial: 0.55 mg/kg/dose given every 6 hours; change to oral after ~4 days, decrease dose gradually over 2-3 weeks (AAP Committee on Drugs, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"      see \"Chlorpromazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;6 months and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schizophrenia/psychoses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 0.5-1 mg/kg/dose every 4-6 hours; older children may require 200 mg/day or higher",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 0.5-1 mg/kg/dose every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maximum recommended doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children &lt;5 years (&lt;22.7 kg): 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children 5-12 years (22.7-45.5 kg): 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nausea and vomiting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 0.5-1 mg/kg/dose every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 0.5-1 mg/kg/dose every 6-8 hours; maximum recommended doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;5 years (&lt;22.7 kg): 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 5-12 years (22.7-45.5 kg): 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schizophrenia/psychoses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Range: 30-800 mg/day in 1-4 divided doses, initiate at lower doses and titrate as needed; usual dose is 200 mg/day; some patients may require 1-2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 25 mg initially, may repeat (25-50 mg) in 1-4 hours, gradually increase to a maximum of 400 mg/dose every 4-6 hours until patient controlled; usual dose 300-800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nausea and vomiting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 10-25 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 25-50 mg every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with water, food, or milk to decrease GI upset. Do not administer chlorpromazine liquid preparations simultaneously with carbamazepine suspension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Do not administer SubQ (tissue damage and irritation may occur); for direct I.V. injection: Dilute with NS to a maximum concentration of 1 mg/mL, administer slow I.V. at a rate not to exceed 0.5 mg/minute in children and 1 mg/minute in adults.",
"     <b>",
"      Note:",
"     </b>",
"     Avoid skin contact with solution; may cause contact dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F150566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amsacrine, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposome, famotidine, fenoldopam, filgrastim, fluconazole, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, ondansetron, oxaliplatin, potassium chloride, propofol, teniposide, thiotepa, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, aztreonam, bivalirudin, cefepime, etoposide phosphate, fludarabine, furosemide, linezolid, melphalan, methotrexate, paclitaxel, pantoprazole, pemetrexed, piperacillin/tazobactam, sargramostim, tigecycline.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Remifentanil",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, benztropine, buprenorphine, butorphanol, diphenhydramine, doxapram, droperidol, fentanyl, glycopyrrolate, hydromorphone, meperidine, metoclopramide, midazolam, pentazocine, prochlorperazine edisylate, promethazine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cimetidine, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dimenhydrinate, heparin, hydroxyzine, morphine, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect oral dosage forms from light; diluted injection (1 mg/mL) with NS stored in 5 mL vials remains stable for 30 days",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nausea and vomiting (FDA approved in ages 6 months to 12 years and adults), restlessness and apprehension prior to surgery (FDA approved in ages 6 months to 12 years and adults), severe behavioral problems in children displayed by combativeness and/or explosive hyperexcitable behavior and in short-term treatment of hyperactive children (FDA approved in ages 1-12 years); schizophrenia (FDA approved in adults), psychotic disorders (FDA approved in adults), mania (FDA approved in adults), acute intermittent porphyria (FDA approved in adults), intractable hiccups (FDA approved in adults), adjunct in the treatment of tetanus (FDA approved in adults); has also been used in Tourette's syndrome and neonatal abstinence syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ChlorproMAZINE may be confused with chlordiazePOXIDE, chlorproPAMIDE, clomiPRAMINE, prochlorperazine, promethazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thorazine may be confused with thiamine, thioridazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Dizziness, nonspecific QT changes, orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Akathisia, drowsiness, dystonias, neuroleptic malignant syndrome, pseudoparkinsonism, seizure, tardive dyskinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, photosensitivity, skin pigmentation (slate gray)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast engorgement, false-positive pregnancy test, gynecomastia, hyper- or hypoglycemia, lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disorder, impotence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, corneal and lenticular changes, epithelial keratopathy, pigmentary retinopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpromazine hydrochloride or any component; cross-sensitivity with other phenothiazines may exist; avoid use in patients with narrow-angle glaucoma, bone marrow suppression, severe liver or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular, renal, or hepatic disease; chronic respiratory diseases (especially in children); seizures; significant medical disorders or children with acute illnesses",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of neuroleptics. Significant hypotension may occur, particularly with parenteral administration. May be sedating; use with caution in disorders in which CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Impaired core body temperature regulation may occur; use with caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects. Relative to other neuroleptics, chlorpromazine has a moderate potency of cholinergic blockade. May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects. Elevates prolactin levels; use with caution in patients with breast cancer or other prolactin-dependent tumors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is low-moderate relative to other neuroleptics, and is dose-dependent; to decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically; risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients). Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability; risk may be increased in patients with Parkinson's disease or Lewy body dementia. May cause pigmentary retinopathy and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature; chlorpromazine is not approved for this indication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tablets may contain benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use chlorpromazine products containing benzoic acid with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Injection contains sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: ChlorproMAZINE may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: ChlorproMAZINE may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE.  Management: Consider alternatives to combined treatment with these agents. If combined treatment cannot be avoided, monitor for signs and symptoms of prolonged QTc interval (e.g. arrhythmias).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: ChlorproMAZINE may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases riboflavin elimination and may induce depletion; some may recommend increasing riboflavin in diet; may also decrease absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     ; brown precipitate may occur when chlorpromazine is mixed with caffeine-containing liquids",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity was observed in animal reproduction studies. Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic eye exam with prolonged therapy; blood pressure with parenteral administration; CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relationship of plasma concentration to clinical response is not well established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 50-300 ng/mL (SI: 157-942 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;750 ng/mL (SI: &gt;2355 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chlorpromazine is an aliphatic phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antipsychotic effects: Gradual, may take up to several weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum antipsychotic effect: 6 weeks to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Oral: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Rapid and virtually complete; large first-pass effect due to metabolism during absorption in the GI mucosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed into most body tissues and fluids; crosses blood-brain barrier and placenta; appears in breast milk; V",
"     <sub>",
"      d",
"     </sub>",
"     : 8-160 L/kg (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 90% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively in the liver by demethylation (followed by glucuronide conjugation) and amine oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: ~32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biphasic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 1.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 7.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: ~30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: &lt;1% excreted in urine as unchanged drug within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20661?source=see_link\">",
"      see \"Chlorpromazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although chlorpromazine has been used in combination with meperidine and promethazine as a premedication (&ldquo;lytic cocktail&rdquo;), this combination may have a higher rate of adverse effects compared to alternative sedatives/analgesics (AAP, 1995). Use decreased doses in elderly or debilitated patients; dystonic reactions may be more common in patients with hypocalcemia; extrapyramidal reactions may be more common in pediatric patients, especially those with dehydration or acute illnesses (viral or CNS infections).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Neonatal Drug Withdrawal,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(6):1079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/35/21047/abstract-text/9614425/pubmed\" id=\"9614425\" target=\"_blank\">",
"        9614425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Reappraisal of Lytic Cocktail/Demerol&reg;, Phenergan&reg;, and Thorazine&reg; (DPT) for the Sedation of Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(4):598-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/35/21047/abstract-text/7700765 /pubmed\" id=\"7700765 \" target=\"_blank\">",
"        7700765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlanut M, Benetello P, Baraldo M, et al, &ldquo;Chlorpromazine Disposition in Relation to Age in Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 18(4):329-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/35/21047/abstract-text/2323156/pubmed\" id=\"2323156\" target=\"_blank\">",
"        2323156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazurier E, Cambonie G, Barbotte E, et al, \"Comparison of Chlorpromazine Versus Morphine Hydrochloride for Treatment of Neonatal Abstinence Syndrome,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2008, 97(10):1358-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/35/21047/abstract-text/18644009/pubmed\" id=\"18644009\" target=\"_blank\">",
"        18644009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13150 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-222.169.60.2-DB8828736C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21047=[""].join("\n");
var outline_f20_35_21047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290573\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150514\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051677\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442238\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051668\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150486\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150470\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051682\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150566\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051672\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051681\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150568\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150565\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051686\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051667\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051666\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150555\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150479\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051689\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923687\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051676\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051680\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051665\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051684\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051685\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051674\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051687\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=related_link\">",
"      Chlorpromazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20661?source=related_link\">",
"      Chlorpromazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21048="Clinical manifestations and causes of central diabetes insipidus";
var content_f20_35_21048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and causes of central diabetes insipidus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21048/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21048/contributors\">",
"     Daniel G Bichet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21048/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21048/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/35/21048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central diabetes insipidus (DI) is characterized by decreased release of antidiuretic hormone (ADH, also called arginine vasopressin or AVP), resulting in a variable degree of polyuria. Lack of ADH can be caused by disorders that act at one or more of the sites involved in ADH secretion: the hypothalamic osmoreceptors; the supraoptic or paraventricular nuclei; or the superior portion of the supraopticohypophyseal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, damage to the tract below the median eminence or to the posterior pituitary generally causes only transient polyuria, because ADH produced in the hypothalamus can still be secreted into the systemic circulation via the portal capillaries in the median eminence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=see_link\">",
"     \"Hypothalamic-pituitary axis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and causes of central DI will be reviewed here. The treatment of central DI, the clinical manifestations and causes of nephrogenic DI, and the diagnostic approach to the polyuric patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141707708\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with untreated central DI typically present with polyuria, nocturia, and, due to the initial elevation in serum sodium and osmolality, polydipsia. They may also have neurologic symptoms related to the underlying neurologic disease.",
"   </p>",
"   <p>",
"    The serum sodium concentration in untreated central DI is often in the high normal range, which is required to provide the ongoing stimulation of thirst to replace the urinary water losses. Moderate to severe hypernatremia can develop when thirst is impaired or cannot be expressed. This can occur in patients with central nervous system lesions who also have hypodipsia or adipsia, in infants and young children who cannot independently access free water, and in the postoperative period in patients with unrecognized DI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H92106445#H92106445\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Adipsic diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with central DI may develop decreased bone mineral density at the lumbar spine and femoral neck, even in those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/2\">",
"     2",
"    </a>",
"    ]. It is unclear how the deficiency of ADH results in bone loss, particularly since treatment fails to prevent bone disease. However, since ADH acts upon both V1 and V2 receptors and desmopressin principally upon V2 receptors, one possible mechanism is that activation of V1 receptors stimulates bone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of central DI (CDI), accounting for the vast majority of cases, are idiopathic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ], primary or secondary tumors or infiltrative diseases (such as Langerhans cell histiocytosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/5\">",
"     5",
"    </a>",
"    ], neurosurgery, and trauma. In a report of 79 children and young adults, for example, central DI was idiopathic in 52 percent and resulted from a tumor or infiltrative disease in 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any form of CDI can be exacerbated or first become apparent during pregnancy, since catabolism of antidiuretic hormone (ADH, also called arginine vasopressin or AVP) is increased by vasopressinases released from the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Idiopathic CDI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 50 percent of cases of CDI are idiopathic, being associated with destruction of the hormone-secreting cells in the hypothalamic nuclei. It has been suggested that an autoimmune process is involved in many, if not most, patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Insight into the mechanism of autoimmunity in some individuals was provided by a longitudinal study evaluating the presence of cytoplasmic antibodies directed against vasopressin cells (Ab-positive) in patients with endocrine autoimmune diseases but initially without CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/9\">",
"     9",
"    </a>",
"    ]. Among almost 900 such patients, 9 found to be Ab-positive and 139 Ab-negative controls were prospectively followed. At four years, none of the controls developed CDI. By comparison, four of the nine Ab-positive patients had partial CDI at study entry and, among the remaining five patients, three developed partial DI and one developed complete CDI.",
"   </p>",
"   <p>",
"    This autoimmune process is characterized by lymphocytic inflammation of the pituitary stalk and posterior pituitary that resolves after destruction of the target neurons. MRI early in the course often reveals thickening or enlargement of these structures.",
"   </p>",
"   <p>",
"    The incidence of such antibodies in those with CDI, their association with other autoimmune diseases, and their correlation with radiologic features was evaluated in a study of 150 patients with central DI that was performed by the same Italian group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/10\">",
"     10",
"    </a>",
"    ]. The disease was idiopathic in 43 percent, familial in 4 percent, granulomatous in 8 percent, and secondary to cranial trauma, tumor, or surgery in 45 percent. Antibodies to vasopressin cells were found in about one-third of the patients with idiopathic disease and approximately one-quarter of patients with nonidiopathic disease. Antibody positivity was independently associated with age less than 30 years at disease onset in those with idiopathic disease, a history of autoimmune disease, or pituitary stalk thickening. Autoimmune CDI was highly probable in young patients with a history of autoimmune disease and pituitary stalk thickening.",
"   </p>",
"   <p>",
"    Thickening of the pituitary stalk is a nonspecific finding, since some patients with this finding later develop a germinoma or histiocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/12\">",
"     12",
"    </a>",
"    ]. In children, progressive thickening of the stalk as determined by serial MRIs is strongly suggestive of a germinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anterior pituitary hormone deficiency, with decreased release of growth hormone, thyroid stimulating hormone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    , also may be present or develop in patients with idiopathic CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. However, some patients who develop an anterior pituitary endocrinopathy years after the diagnosis of CDI may have a pituitary or suprasellar tumor, suggesting that the initial abnormality was due to an occult pathologic process. As an example, in one study of 16 patients first diagnosed with idiopathic CDI, the detection of evolving gonadotropin deficiency in three individuals resulted in the diagnosis of pituitary or suprasellar germinomas 20, 6, and 3 years after the initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/14\">",
"     14",
"    </a>",
"    ]. These data, if confirmed, suggest that such patients should undergo regular endocrine follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Familial and congenital disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of familial and congenital diseases have been associated with CDI. These include familial CDI, Wolfram syndrome, and congenital diseases such as congenital hypopituitarism and septo-optic dysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718364857\">",
"    <span class=\"h3\">",
"     Familial CDI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial CDI, also called familial neurohypophyseal diabetes insipidus or FNDI (MIM 125700), is usually an autosomal dominant disease caused by mutations in the gene encoding antidiuretic hormone (ADH, also called arginine vasopressin or AVP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/15\">",
"     15",
"    </a>",
"    ]. ADH and its corresponding carrier, neurophysin II, are synthesized as a composite precursor by the magnocellular neurons of the supraoptic and paraventricular nuclei of the hypothalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which a single mutant allele causes autosomal dominant FNDI involves the induction of magnocellular cell death by the accumulation of misfolded AVP precursors within the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/17\">",
"     17",
"    </a>",
"    ]. Transfection studies in mouse neuroblastoma Neuro 2A cells suggest that the mechanism(s) by which a dominant mutant allele causes neurogenic diabetes insipidus is a result of the accumulation of arginine-vasopressin fibrillar aggregates within the endoplasmic reticulum, a so-called toxic gain-of-function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/18\">",
"     18",
"    </a>",
"    ]. This process is mechanistically similar to that seen in other neurodegenerative diseases, such as Huntington and Parkinson diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/19\">",
"     19",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Although the handling of misfolded AVP mutants could account for the delayed onset and progressive nature of dominant FNDI, the precise mechanism of magnocellular toxicity is still unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/18\">",
"     18",
"    </a>",
"    ]. Individuals with autosomal dominant disease progressively develop AVP deficiency, and clinical and hormonal signs usually do not develop until several months or years after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This autosomal dominant form of central DI contrasts with congenital AVP deficiency that has been described in three families with autosomal recessive central DI. Two families bear a missense variation affecting the seventh amino acid of the AVP nonapeptide (p.Pro26Leu) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and four members of one family with two loops of inbreeding bear a large deletion involving the majority of the AVP",
"    <strong>",
"    </strong>",
"    gene as well as the intergenic region between the AVP and OXT gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/23\">",
"     23",
"    </a>",
"    ]. Affected members have early polyuria and hypernatremia, in contrast to the autosomal dominant disease mentioned above. The existence of this autosomal recessive, early onset central DI is important because it must be considered, along with congenital nephrogenic DI, in the differential diagnosis of congenital polyuria and dehydration, and therapy for these disorders differ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718364872\">",
"    <span class=\"h3\">",
"     Wolfram syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wolfram or DIDMOAD syndrome is characterized by CDI, diabetes mellitus, optic atrophy, and deafness; it is inherited as an autosomal recessive trait with incomplete penetrance. The Wolfram syndrome is caused by at least two different genes: WFS1 and ZCD2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/24\">",
"     24",
"    </a>",
"    ]. Both encode endoplasmic reticulum proteins and seem to affect calcium homeostasis. Wolframin, the product of WFS1, is expressed in a number of tissues, including the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/25\">",
"     25",
"    </a>",
"    ] and brain supraoptic paraventricular nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/26\">",
"     26",
"    </a>",
"    ]. Diabetes insipidus in this disorder is due to loss of vasopressin-secreting neurons in the supraoptic nucleus and impaired processing of vasopressin precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in WFS1 also predispose to type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/28\">",
"     28",
"    </a>",
"    ]. WFS1 negatively regulates a key transcription factor involved in endoplasmic reticulum (ER) stress signaling, resulting in pancreatic beta cell death and possibly in magnocellular cell death, which could explain the vasopressin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link&amp;anchor=H19#H19\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Wolfram syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798843467\">",
"    <span class=\"h3\">",
"     Congenital hypopituitarism",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDI has been described in patients with congenital hypopituitarism with or without ectopia of the posterior pituitary lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The defects in posterior pituitary function in these disorders include symptomatic CDI, nocturia, reduced ADH release after osmotic challenge, and hypodipsia or polydipsia. These findings may be associated with isolated growth hormone deficiency or multiple anterior pituitary hormone deficiencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718365022\">",
"    <span class=\"h3\">",
"     Septo-optic dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDI can be seen in a number of congenital cerebral midline abnormalities. As an example, septo-optic dysplasia (SOD) has been associated with defects in both anterior and posterior pituitary function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. SOD is a highly heterogeneous condition with phenotypes that include midline and forebrain abnormalities as well as optic nerve and pituitary hypoplasia. Most cases of SOD are sporadic, but familial cases have been described in association with mutations in genes for developmental transcription factors (such as HESX1) that are essential for normal",
"    <span class=\"nowrap\">",
"     forebrain/pituitary",
"    </span>",
"    development [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/35\">",
"     35",
"    </a>",
"    ]. Affected patients may have abnormal thirst as well as a defect in ADH release [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. As a result, we recommend monitoring of the serum sodium in these patients once per week for one month, and then if stable, once every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurosurgery or trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDI can be induced by neurosurgery (usually transsphenoidal) or trauma to the hypothalamus and posterior pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. The incidence of CDI in these patients varies with the extent of injury, ranging from 10 to 20 percent after transsphenoidal removal of an adenoma limited to the sella to as high as 60 to 80 percent after removal of very large tumors.",
"   </p>",
"   <p>",
"    A much lower rate of postoperative CDI has been reported with minimally invasive endoscopic pituitary surgery (2.7 percent permanent and 13.6 percent transient) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/42\">",
"     42",
"    </a>",
"    ]. A serum sodium higher than 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within the first five days postoperatively had a high predictive value for permanent DI development. In contrast, patients with a serum sodium less than 145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first five days postoperatively will rarely, if ever, develop permanent DI, thereby validating short postoperative inpatient stays with minimal risk of readmission for DI management.",
"   </p>",
"   <p>",
"    Craniopharyngioma has been associated with CDI both before surgery and particularly after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/39,43\">",
"     39,43",
"    </a>",
"    ]. A somewhat different response has been detected after transfrontal surgery for a craniopharyngioma. In this setting, the polyuria appears to result in at least some patients from the release of an ADH precursor from the hypothalamus that competes for but does not activate ADH V2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/41\">",
"     41",
"    </a>",
"    ]. These patients initially have high serum immunoreactive ADH concentrations, but their ADH has little or no biological activity and they have diminished response to exogenous hormone replacement. Thus, they behave as if they have nephrogenic DI (NDI), although the polyuria is typically transient.",
"   </p>",
"   <p>",
"    Severe damage to the hypothalamus or tract by neurosurgery or trauma often results in a typical",
"    <strong>",
"     triphasic",
"    </strong>",
"    response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. There is an initial polyuric phase, beginning within 24 hours and lasting 4 to 5 days; this phase reflects inhibition of ADH release due to hypothalamic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/37\">",
"     37",
"    </a>",
"    ]. This is followed, on days 6 to 11, by an antidiuretic phase in which stored hormone is slowly released from the degenerating posterior pituitary. During this stage, excessive water intake can lead to hyponatremia because of a transient syndrome of inappropriate ADH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/44\">",
"     44",
"    </a>",
"    ]. Permanent DI may then ensue after the posterior pituitary stores are depleted.",
"   </p>",
"   <p>",
"    Most cases are not permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/45\">",
"     45",
"    </a>",
"    ]. As an example, patients with less severe hypothalamic or tract injury often have transient CDI that begins 24 to 48 hours after surgery and may then resolve over the first week. Furthermore, not all patients progress through all three phases. Some patients develop transient hyponatremia, with or without preceding polyuria, and then recover. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of 1571 patients with pituitary adenomas of all types who underwent transsphenoidal surgery at the same center provides insight into the relative frequency of these different responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/46\">",
"     46",
"    </a>",
"    ]. Among these patients, 30 percent had microadenomas and 70 percent macroadenomas. The key findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      31 percent had immediate postoperative polyuria, 17 percent had polyuria on day three, and 6 percent on day seven. Of these patients, 24 percent received one or more doses of ADH. After three months, only 0.9 percent were still receiving ADH or had polyuria.",
"     </li>",
"     <li>",
"      3.4 percent of patients had transient polyuria and then transient hyponatremia.",
"     </li>",
"     <li>",
"      1.1 percent had the triphasic pattern of polyuria, hyponatremia, and then polyuria.",
"     </li>",
"     <li>",
"      5.2 percent had only transient hyponatremia, either within one to three days or five to ten days after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the relatively high frequency of CDI in patients undergoing neurosurgery, most cases of polyuria in this setting are",
"    <strong>",
"     not",
"    </strong>",
"    due to CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/37\">",
"     37",
"    </a>",
"    ]. More common causes are excretion of excess fluid administered during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/47\">",
"     47",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an osmotic diuresis induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    or glucocorticoids (which cause hyperglycemia and glucosuria) given in an attempt to reduce cerebral edema. These conditions can be differentiated from CDI by measuring the urine osmolality and the response to water restriction and the administration of ADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CDI after neurosurgery rarely occurs in combination with cerebral salt-wasting. Depending upon the balance of the ensuing water and solute (NaCl) diuresis, hyponatremia, normonatremia, or hypernatremia may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Cerebral salt wasting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary or secondary (most often due to lung cancer, leukemia, or lymphoma) tumors in the brain can involve the hypothalamic-pituitary region and lead to CDI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/3\">",
"     3",
"    </a>",
"    ]. In some patients with metastatic disease, polyuria is the presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypoxic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxic encephalopathy or severe ischemia (as with cardiopulmonary arrest or shock) can lead to diminished ADH release [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/1,49\">",
"     1,49",
"    </a>",
"    ]. The severity of this defect varies, ranging from mild and asymptomatic to marked polyuria. As an example, overt CDI is unusual in patients with Sheehan's syndrome (postpartum hypopituitarism) even though ADH secretion is often subnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/50\">",
"     50",
"    </a>",
"    ]. The appearance of DI in these patients is consistent with the occasional pathologic findings of scarring and atrophy in the supraoptic nuclei and posterior pituitary gland [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"     \"Causes of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infiltrative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Langerhans cell histiocytosis (also called histiocytosis X and eosinophilic granuloma) are at particularly high risk for CDI due to hypothalamic-pituitary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/5,52\">",
"     5,52",
"    </a>",
"    ]. Up to 40 percent of patients become polyuric within the first four years, particularly if there is multisystem involvement and proptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar infiltrative disease can occur with sarcoidosis, which can also cause polyuria due to NDI (induced by hypercalcemia) or primary polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/53\">",
"     53",
"    </a>",
"    ]. Additional infiltrative disorders that rarely cause CDI include granulomatosis with polyangiitis (formerly Wegener's granulomatosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and autoimmune lymphocytic hypophysitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/8,56-58\">",
"     8,56-58",
"    </a>",
"    ]; the latter disorder may spontaneously improve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes of hypopituitarism\", section on 'Hypophysitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Post-supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient polyuria is occasionally seen after correction of a supraventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Both a water diuresis and a natriuresis may be seen, due respectively due to decreased secretion of ADH and to increased release of atrial natriuretic peptide. These humoral changes may be mediated by increases in left atrial and systemic pressure, thereby activating local volume receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADH release is often subnormal or erratic in patients with anorexia nervosa, presumably due to the cerebral dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21048/abstract/61\">",
"     61",
"    </a>",
"    ]. This defect is relatively mild in most cases and polyuria, when present, is often due mostly to a primary increase in thirst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=see_link\">",
"       \"Patient information: Diabetes insipidus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121215144\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central diabetes insipidus (CDI) is characterized by decreased release of antidiuretic hormone (ADH), resulting in a variable degree of polyuria. Lack of ADH can be caused by disorders that act at one or more of the sites involved in ADH secretion: the hypothalamic osmoreceptors; the supraoptic or paraventricular nuclei; or the superior portion of the supraopticohypophyseal tract. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with untreated CDI typically present with polyuria, nocturia, and, due to the initial elevation in serum sodium and osmolality, polydipsia. They may also have neurologic symptoms related to the underlying neurologic disease. (See",
"      <a class=\"local\" href=\"#H141707708\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of central DI include idiopathic disease, familial and congenital disorders, neurosurgery or trauma, primary or secondary cancers, hypoxic encephalopathy, infiltrative disorders, post-supraventricular tachycardia, and anorexia nervosa. The vast majority of cases are due to idiopathic CDI or result from primary or secondary tumors, or infiltrative diseases (such as Langerhans cell histiocytosis). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 751-754.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/2\">",
"      Pivonello R, Colao A, Di Somma C, et al. Impairment of bone status in patients with central diabetes insipidus. J Clin Endocrinol Metab 1998; 83:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/3\">",
"      Kimmel DW, O'Neill BP. Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 1983; 52:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/4\">",
"      Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/5\">",
"      Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/6\">",
"      Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/7\">",
"      Lindheimer MD. Polyuria and pregnancy: its cause, its danger. Obstet Gynecol 2005; 105:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/8\">",
"      Imura H, Nakao K, Shimatsu A, et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993; 329:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/9\">",
"      De Bellis A, Colao A, Di Salle F, et al. A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab 1999; 84:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/10\">",
"      Pivonello R, De Bellis A, Faggiano A, et al. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. J Clin Endocrinol Metab 2003; 88:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/11\">",
"      De Bellis A, Colao A, Bizzarro A, et al. Longitudinal study of vasopressin-cell antibodies and of hypothalamic-pituitary region on magnetic resonance imaging in patients with autoimmune and idiopathic complete central diabetes insipidus. J Clin Endocrinol Metab 2002; 87:3825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/12\">",
"      Leger J, Velasquez A, Garel C, et al. Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus. J Clin Endocrinol Metab 1999; 84:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/13\">",
"      Czernichow P, Pomarede R, Basmaciogullari A, et al. Diabetes insipidus in children. III. Anterior pituitary dysfunction in idiopathic types. J Pediatr 1985; 106:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/14\">",
"      Charmandari E, Brook CG. 20 years of experience in idiopathic central diabetes insipidus. Lancet 1999; 353:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/15\">",
"      Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus--an update. Semin Nephrol 2006; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/16\">",
"      Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001; 81:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/17\">",
"      Russell TA, Ito M, Ito M, et al. A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 2003; 112:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/18\">",
"      Birk J, Friberg MA, Prescianotto-Baschong C, et al. Dominant pro-vasopressin mutants that cause diabetes insipidus form disulfide-linked fibrillar aggregates in the endoplasmic reticulum. J Cell Sci 2009; 122:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/19\">",
"      Gregersen N, Bross P, Vang S, Christensen JH. Protein misfolding and human disease. Annu Rev Genomics Hum Genet 2006; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/20\">",
"      McLeod JF, Kov&aacute;cs L, Gaskill MB, et al. Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab 1993; 77:599A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/21\">",
"      Willcutts MD, Felner E, White PC. Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 1999; 8:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/22\">",
"      Abu Libdeh A, Levy-Khademi F, Abdulhadi-Atwan M, et al. Autosomal recessive familial neurohypophyseal diabetes insipidus: onset in early infancy. Eur J Endocrinol 2010; 162:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/23\">",
"      Christensen JH, Kvistgaard H, Knudsen J, et al. A novel deletion partly removing the AVP gene causes autosomal recessive inheritance of early-onset neurohypophyseal diabetes insipidus. Clin Genet 2013; 83:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/24\">",
"      Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet 2007; 81:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/25\">",
"      Ishihara H, Takeda S, Tamura A, et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004; 13:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/26\">",
"      Takeda K, Inoue H, Tanizawa Y, et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/27\">",
"      Gabre&euml;ls BA, Swaab DF, de Kleijn DP, et al. The vasopressin precursor is not processed in the hypothalamus of Wolfram syndrome patients with diabetes insipidus: evidence for the involvement of PC2 and 7B2. J Clin Endocrinol Metab 1998; 83:4026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/28\">",
"      Sandhu MS, Weedon MN, Fawcett KA, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007; 39:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/29\">",
"      Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 2010; 120:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/30\">",
"      Yagi H, Nagashima K, Miyake H, et al. Familial congenital hypopituitarism with central diabetes insipidus. J Clin Endocrinol Metab 1994; 78:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/31\">",
"      Lukezic M, Righini V, Di Natale B, et al. Vasopressin and thirst in patients with posterior pituitary ectopia and hypopituitarism. Clin Endocrinol (Oxf) 2000; 53:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/32\">",
"      Yamanaka C, Momoi T, Fujisawa I, et al. Neurohypophyseal function of an ectopic posterior lobe in patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1990; 122:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/33\">",
"      Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS. Septo-optic dysplasia and pituitary dwarfism. Lancet 1970; 1:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/34\">",
"      Masera N, Grant DB, Stanhope R, Preece MA. Diabetes insipidus with impaired osmotic regulation in septo-optic dysplasia and agenesis of the corpus callosum. Arch Dis Child 1994; 70:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/35\">",
"      McCabe MJ, Alatzoglou KS, Dattani MT. Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best Pract Res Clin Endocrinol Metab 2011; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/36\">",
"      Secco A, Allegri AE, di Iorgi N, et al. Posterior pituitary (PP) evaluation in patients with anterior pituitary defect associated with ectopic PP and septo-optic dysplasia. Eur J Endocrinol 2011; 165:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/37\">",
"      Seckl J, Dunger D. Postoperative diabetes insipidus. BMJ 1989; 298:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/38\">",
"      Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005; 103:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/39\">",
"      Ghirardello S, Hopper N, Albanese A, Maghnie M. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006; 19 Suppl 1:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/40\">",
"      Hadjizacharia P, Beale EO, Inaba K, et al. Acute diabetes insipidus in severe head injury: a prospective study. J Am Coll Surg 2008; 207:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/41\">",
"      Seckl JR, Dunger DB, Bevan JS, et al. Vasopressin antagonist in early postoperative diabetes insipidus. Lancet 1990; 335:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/42\">",
"      Sigounas DG, Sharpless JL, Cheng DM, et al. Predictors and incidence of central diabetes insipidus after endoscopic pituitary surgery. Neurosurgery 2008; 62:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/43\">",
"      Crowley RK, Hamnvik OP, O'Sullivan EP, et al. Morbidity and mortality in patients with craniopharyngioma after surgery. Clin Endocrinol (Oxf) 2010; 73:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/44\">",
"      Hoorn EJ, Zietse R. Water balance disorders after neurosurgery: the triphasic response revisited. NDT Plus 2010; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/45\">",
"      Olson BR, Gumowski J, Rubino D, Oldfield EH. Pathophysiology of hyponatremia after transsphenoidal pituitary surgery. J Neurosurg 1997; 87:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/46\">",
"      Hensen J, Henig A, Fahlbusch R, et al. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf) 1999; 50:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/47\">",
"      Bohn D, Davids MR, Friedman O, Halperin ML. Acute and fatal hyponatraemia after resection of a craniopharyngioma: a preventable tragedy. QJM 2005; 98:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/48\">",
"      Laredo S, Yuen K, Sonnenberg B, Halperin ML. Coexistence of central diabetes insipidus and salt wasting: the difficulties in diagnosis, changes in natremia, and treatment. J Am Soc Nephrol 1996; 7:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/49\">",
"      Wickramasinghe LS, Chazan BI, Mandal AR, et al. Cranial diabetes insipidus after upper gastrointestinal hemorrhage. Br Med J (Clin Res Ed) 1988; 296:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/50\">",
"      Bakiri F, Benmiloud M, Vallotton MB. Arginine-vasopressin in postpartum panhypopituitarism: urinary excretion and kidney response to osmolar load. J Clin Endocrinol Metab 1984; 58:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/51\">",
"      Jialal I, Desai RK, Rajput MC. An assessment of posterior pituitary function in patients with Sheehan's syndrome. Clin Endocrinol (Oxf) 1987; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/52\">",
"      Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med 1989; 321:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/53\">",
"      Stuart CA, Neelon FA, Lebovitz HE. Disordered control of thirst in hypothalamic-pituitary sarcoidosis. N Engl J Med 1980; 303:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/54\">",
"      Garovic VD, Clarke BL, Chilson TS, Specks U. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis 2001; 37:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/55\">",
"      Czarnecki EJ, Spickler EM. MR demonstration of Wegener granulomatosis of the infundibulum, a cause of diabetes insipidus. AJNR Am J Neuroradiol 1995; 16:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/56\">",
"      Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/57\">",
"      Sato N, Sze G, Endo K. Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol 1998; 19:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/58\">",
"      Nishioka H, Ito H, Fukushima C. Recurrent lymphocytic hypophysitis: case report. Neurosurgery 1997; 41:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/59\">",
"      Canepa-Anson R, Williams M, Marshall J, et al. Mechanism of polyuria and natriuresis in atrioventricular nodal tachycardia. Br Med J (Clin Res Ed) 1984; 289:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/60\">",
"      Fujii T, Kojima S, Imanishi M, et al. Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. Am J Cardiol 1991; 68:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21048/abstract/61\">",
"      Gold PW, Kaye W, Robertson GL, Ebert M. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. N Engl J Med 1983; 308:1117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2373 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21048=[""].join("\n");
var outline_f20_35_21048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H121215144\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141707708\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Idiopathic CDI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Familial and congenital disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718364857\">",
"      - Familial CDI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718364872\">",
"      - Wolfram syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H798843467\">",
"      - Congenital hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718365022\">",
"      - Septo-optic dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurosurgery or trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypoxic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infiltrative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Post-supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H121215144\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=related_link\">",
"      Hypothalamic-pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=related_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21049="Abacavir hypersensitivity reaction";
var content_f20_35_21049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abacavir hypersensitivity reaction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Elizabeth J Phillips, MD, FRCPC, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Simon A Mallal, MBBS, FRACP, FRCPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21049/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21049/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/35/21049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    is a guanosine nucleoside analog with potent activity against HIV. However, in the premarketing phase of drug development, multiple reports emerged of a hypersensitivity syndrome associated with abacavir, which led to significant morbidity. Rare reports of mortality were associated with failure to recognize this clinical syndrome as drug hypersensitivity.",
"   </p>",
"   <p>",
"    Research into this syndrome has demonstrated a host predisposition to this drug-associated hypersensitivity reaction, which is based on immunogenetics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent studies have demonstrated improved drug safety when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    use is restricted to patients without this genetic predisposition. This is the first time that an immunogenetic marker has been used in clinical practice to prevent a specific drug toxicity.",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, immunogenetics, clinical manifestations, clinical management, and screening recommendations for the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity reaction (AHR). Indications for use of abacavir as part of combination antiretroviral therapy (ART) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"human leukocyte antigen (HLA) system\" is synonymous with the human major histocompatibility complex (MHC). These terms describe a group of genes on chromosome 6 that encode a variety of cell surface markers, antigen-presenting molecules, and other proteins involved in immune function. The HLA region is divided into three classes and there are three different class I antigens (HLA-A, -B, -C). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal task of the immune system is to recognize and respond to potential pathogens without reacting to the normal components of the individual. Class I HLA molecules present peptide fragments of foreign antigens to CD8+ T cells, which generally have",
"    <span class=\"nowrap\">",
"     cytotoxic/suppressor",
"    </span>",
"    function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMUNOGENETIC BASIS FOR AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA associations with certain rheumatic diseases have been known for several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/2\">",
"     2",
"    </a>",
"    ]. However, interest in HLA background as a potential risk factor for certain drug reactions has only become well defined over the past few years. Associations have been drawn between severe hypersensitivity reactions to particular drugs and specific class I MHC backgrounds. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    (HLA-B*5801),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    (HLA-B*1502), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    (HLA-B*5701) and flucloxacillin (HLA-B*5701) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strong body of evidence from both basic science and clinical research has demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity is exclusively restricted by the HLA allele HLA-B*5701 and is mediated by the activation of CD8+ T-lymphocytes that then release inflammatory cytokines and result in the clinical syndrome of AHR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. The precise mechanism for this has been revealed by biochemical and structural studies showing that abacavir binds non-covalently to the floor of the peptide binding groove of HLA-B*5701 with exquisite specificity to alter the self-peptides that are presented to the immune system (",
"    <a class=\"graphic graphic_figure graphicRef86765 \" href=\"UTD.htm?25/30/26084\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. This specificity explains the 100 percent negative predictive value of HLA-B*5701 testing for hypersensitivity, which underpins its utility as a screening test. The rapid and direct non-covalent binding of abacavir to HLA-B*5701 without the requirement for metabolism of the drug also explains the clinical symptoms of hypersensitivity, including dose-related escalation of symptoms and rapid offset of symptoms following drug cessation.",
"   </p>",
"   <p>",
"    Ex vivo data strongly support a role for cytotoxic T-cells in the pathogenesis of AHR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The production of interferon-gamma was specifically induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      exposure in peripheral blood mononuclear cells (PBMCs) obtained from hypersensitive patients carrying the HLA-B*5701 allele compared to tolerant controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a history of AHR had increased levels of tumor necrosis factor (TNF-alpha) in response to ex vivo",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      stimulation; these responses were abrogated by CD8+ T-cell depletion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/5,6,8\">",
"       5,6,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Significant CD8 T-cell proliferation in response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      stimulation occurred in patients with a positive abacavir skin patch test compared to stimulation with control antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/9\">",
"       9",
"      </a>",
"      ]. Furthermore, skin biopsies from both the skin rash of AHR and a positive patch test following AHR have demonstrated abundant CD8+ T cells. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Skin patch testing'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to its role in AHR, HLA-B*5701 has been shown to play an important role in HIV control, viral set point, and has been overrepresented in populations of long-term nonprogressors and elite controllers. HLA-B*5701 is associated with early, broad, and strong HIV-specific T-cell responses, particularly to epitopes in the gag protein. The virus cannot mutate to escape these responses without incurring a large loss of replicative capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link\">",
"     \"Factors affecting HIV progression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of AHR varies according to whether it is defined by clinical symptoms alone or with supportive diagnostic testing, such as skin patch testing. Since the manifestations are nonspecific, AHR can be confused with other clinical syndromes, leading to substantial overdiagnosis (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical diagnosis of AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early postmarketing experience, AHR was described in 4 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large retrospective review of 200,000 patients exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (from 1996 to 2000) was undertaken to determine the incidence of abacavir-related hypersensitivity events [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/15\">",
"       15",
"      </a>",
"      ]. Cases were classified as definitive or probable; definitive cases included patients whose symptoms returned on reexposure to drug. Based on the 1302 cases identified in clinical trials, the calculated incidence of hypersensitivity was 4 percent.",
"     </li>",
"     <li>",
"      A prospective clinical trial, which evaluated whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      could be given once daily rather than twice daily, found that the incidence of AHR was similar regardless of dosing frequency (9 versus 7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Association of AHR and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , AHR became the main reason for drug discontinuation in approximately 8 percent of treated patients. No obvious risk factors emerged for this syndrome, although the incidence of this reaction appeared to vary according to race:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 725 patients who underwent HLA-B*5701 screening (one-third of whom were African-American), 5.7 percent of the participants overall were HLA-B*5701-positive, including 7.2 percent of whites and 2.8 percent of blacks [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multivariate analysis of 5332",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      -exposed patients found that the risk was generally lower in blacks than among other ethnic groups (3 percent hypersensitivity; OR 0.59; 95% CI 0.38-0.91) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVIDENCE OF LINK BETWEEN HLA BACKGROUND AND AHR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Carriage rates of HLA-B*5701 and risk of AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2002, two independent groups found a strong association between AHR and carriage of the major histocompatibility complex class I allele HLA-B*5701 marker [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of Australian patients exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , HLA-B*5701 was present in 14 (78 percent) of the 18 patients with abacavir hypersensitivity and in 4 (2 percent) of the 167 abacavir-tolerant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective, case-control study of mainly white HIV-infected men, HLA-B*5701 was present in 39 (46 percent) of 84 patients clinically diagnosed with AHR versus 4 (4 percent) of 113 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in mainly white populations suggested HLA-B*5701 carriage rates of approximately 4 to 8 percent (",
"    <a class=\"graphic graphic_figure graphicRef62217 \" href=\"UTD.htm?3/32/3592\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The carriage rate of HLA-B*5701 in American Blacks is thought to be 2 to 3 percent; however, rates of &lt;1 percent have been cited in certain African and Asian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/24\">",
"     24",
"    </a>",
"    ]. Frequencies in smaller and rarer populations can be found at",
"    <a class=\"external\" href=\"file://www.allelefrequencies.net\">",
"     www.allelefrequencies.net",
"    </a>",
"    as this information becomes available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Testing performance among different racial populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it was initially perceived that HLA testing lacked predictive value across all racial groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/25\">",
"     25",
"    </a>",
"    ], a retrospective case-control study using patch test confirmation has shown that HLA-B*5701 was a sensitive test for AHR regardless of race [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients were identified through chart review and were classified as having AHR either through clinical suspicion alone (defined as having at least two symptoms or signs consistent with AHR) or based on clinical findings supplemented with a positive skin patch test. Control subjects were racially matched patients who had tolerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    for at least 12 weeks. A skin patch test was used to define patients with true immunologically mediated AHR. The study demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-two (32 percent) of 130 white patients and 5 (7 percent) of 69 black patients who had clinically suspected AHR also had a positive skin patch test.",
"     </li>",
"     <li>",
"      All white patients with immunologically confirmed disease were HLA-B*5701-positive (100 percent sensitivity); among white patients with clinically suspected AHR, the sensitivity was only 44 percent (ie, 57 of 130 patients tested positive for HLA-B*5701). Specificity among white control patients was 96 percent.",
"     </li>",
"     <li>",
"      Among black patients with immunologically confirmed disease, 5 of 5 were HLA-B*5701-positive (100 percent sensitivity); among patients with clinically suspected AHR, the sensitivity was only 14 percent (10 of 69 tested positive for HLA-B*5701). Specificity among black control patients was 99 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that although immunologically confirmed cases of AHR are less common in black persons, HLA-B*5701 still performed extremely well as an immunogenetic marker of risk. This study also demonstrated that false positive clinical diagnoses overshadow true immunologically-mediated hypersensitivity reactions, particularly in low prevalence races. The sensitivity and specificity of HLA-B*5701 testing is discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that include patch test-confirmed patients demonstrate that AHR is a multisystem disease comprising two or more systems [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26-37\">",
"     26-37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    AHR typically presents with a combination of symptoms including fever (which is almost always present), constitutional symptoms (eg, malaise, dizziness, and headache), and gastrointestinal disturbances (eg, nausea, vomiting, diarrhea) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/15,26-37\">",
"     15,26-37",
"    </a>",
"    ]. In one retrospective study, respiratory symptoms (eg, dyspnea, cough) occurred in approximately one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/15\">",
"     15",
"    </a>",
"    ]. The median time to onset of symptoms in patch test-confirmed cases is seven to eight days, although symptoms have been reported within one to two days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In a large trial of patients initiating abacavir, hypersensitivity reactions that were patch-test confirmed presented within three weeks of starting abacavir [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rash is often a late symptom that is absent in up to 30 percent of patients with AHR. In addition, up to 3 percent of patients will develop isolated rash without other symptoms, and this does not constitute AHR.",
"   </p>",
"   <p>",
"    Signs may also include tachycardia and hypotension, particularly on rechallenge. One case series also reported large painful cervical and axillary lymph nodes in association with AHR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Skin patch testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current diagnostic approach to AHR is based on clinical diagnosis and the presentation of multiple symptoms and signs compatible with AHR, as there is no diagnostic test that has been shown to have 100 percent sensitivity.",
"   </p>",
"   <p>",
"    HLA-B*5701 is useful as a genetic screening test before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    is prescribed. Since it remains theoretically possible that a second rare HLA allele may also mediate AHR, HLA-B*5701 should NOT be used as a diagnostic test for AHR after the drug has been started. Thus, a negative HLA-B*5701 result should not be used to eliminate the diagnosis of AHR in previously exposed patients who developed a compatible clinical syndrome; such an approach has not been studied and carries the potential risk of morbidity and mortality with rechallenge in a patient with a rare predisposing HLA allele.",
"   </p>",
"   <p>",
"    Similarly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    patch testing has less than 100 percent diagnostic sensitivity and a negative patch test should not be used as the basis for abacavir rechallenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     AVAILABLE TESTING METHODS FOR AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for HLA-B*5701 represents a major advance in the care of HIV-infected patients and remains the mainstay in preventing AHR and its associated morbidity and mortality.",
"   </p>",
"   <p>",
"    Ideally, all patients should be screened for HLA-B*5701 prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    therapy. However, if testing is not available, abacavir can be initiated in conjunction with a clinical management program. Abacavir should be promptly discontinued in any patient who develops multiple symptoms and signs compatible with AHR whether or not genetic screening has been done.",
"   </p>",
"   <p>",
"    Rechallenge with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    in patients who have a documented clinical syndrome compatible with AHR is not recommended. In contrast, patients who have been \"labeled\" with a diagnosis of AHR, but whose clinical syndrome was clearly not compatible with AHR (eg, single symptom disease, such as isolated skin rash) can have abacavir reintroduced, if their HLA-B*5701 screening test is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sensitivity and specificity of HLA-B*5701 screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial doubt was cast on the generalizability of HLA-B*5701 testing since further studies showed particularly low sensitivities of HLA-B*5701 for clinically diagnosed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity in black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/20,25\">",
"     20,25",
"    </a>",
"    ]. However, it became apparent that false positive clinical diagnoses were responsible for this discrepancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/5\">",
"     5",
"    </a>",
"    ]. This was further supported by the consistent 2 to 7 percent rates of clinically diagnosed abacavir hypersensitivity reaction in the non-abacavir arm of randomized double blinded placebo-controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective, case-control study (SHAPE) in a racially diverse population showed 100 percent sensitivity of HLA-B*5701 for skin patch-confirmed AHR, suggesting a 100 percent negative predictive value of HLA-B*5701 testing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity in patients of both white and black race [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26\">",
"     26",
"    </a>",
"    ]. This study supported broad applicability of genetic screening. The implications of screening in a model incorporating white and black race are shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef64846 \" href=\"UTD.htm?3/35/3647\">",
"     algorithm 1",
"    </a>",
"    ). Details of this study are discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evidence of Link between HLA background and AHR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The 100 percent negative predictive value of HLA-B*5701 screening was confirmed in clinical trials of prospective screening prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    exposure. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Screening prior to abacavir exposure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Skin patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin patch testing helps to define those patients with a history of possible AHR with true immunogenetically-mediated disease versus a false positive clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/9,28,31\">",
"     9,28,31",
"    </a>",
"    ]. Experience to date suggests that only those genetically susceptible patients who are \"immunologically primed\" by prior ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    exposure will develop a positive patch test. Thus, skin patch testing can only be reliably performed to characterize patients with a history of possible AHR, and patch testing is not helpful for predicting risk of AHR in unexposed patients.",
"   </p>",
"   <p>",
"    Skin patch testing has also helped to reinforce the strong association between HLA-B*5701 and AHR. For example, of 95 patients with clinically suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity and positive patch tests described in three studies, 100 percent have carried HLA-B*5701 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a negative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    patch test result can neither rule out AHR nor be used to justify rechallenge with abacavir [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/28\">",
"     28",
"    </a>",
"    ]. In the PREDICT-1 study, the diagnostic sensitivity of abacavir skin patch testing was calculated to be 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. A negative patch test in the setting of clinically suspected AHR may be due to a false positive clinical diagnosis or, less commonly, a false negative skin patch test result. Patients with a past history clinically compatible with AHR should be evaluated and treated as described above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patch testing procedure, as validated in previous studies, entails applying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    in concentrations of 1 percent and 10 percent in petrolatum and controls with readings at 24 and 48 hours after patch application. Patch test reagents are not commercially available but are available for academic research (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Monitoring of patients on abacavir'",
"    </a>",
"    below). A positive patch-test result, measured by a visible and palpable cutaneous response, implies a delayed hypersensitivity response to abacavir in previously exposed patients with immunologic priming (",
"    <a class=\"graphic graphic_picture graphicRef81086 \" href=\"UTD.htm?36/36/37444\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51023 \" href=\"UTD.htm?32/57/33695\">",
"     figure 3",
"    </a>",
"    ). The patch test has been demonstrated to be reliable even in patients with a remote history of abacavir hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of AHR are nonspecific and can be difficult to distinguish from other etiologies. This problem of false positive clinical diagnosis was highlighted in randomized, double-blinded, controlled clinical trials, where AHR was reported in 2 to 7 percent of patients who were not receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity syndrome includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious processes (eg, influenza) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immune restoration syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"       \"Immune reconstitution inflammatory syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other drug-related adverse events (eg, rash or diarrhea)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of 15 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity and 30 patients with influenza, rash and gastrointestinal symptoms were noted in approximately half of the patients with AHR versus 6 percent of those with influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-associated rash is an important cause of drug discontinuation in HIV-infected patients and is associated with other antiretroviral agents besides",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ), or antibacterials (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diarrhea and other gastrointestinal symptoms are commonly associated with many agents in the protease inhibitor class; in AHR gastrointestinal symptoms are usually associated with other constitutional symptoms are well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    should be immediately discontinued in any patient who develops clinical signs and symptoms consistent with AHR, whether or not the patient has had genetic screening [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/21\">",
"     21",
"    </a>",
"    ]. Symptoms usually remit promptly after drug discontinuation. Treatment during this time is mainly supportive. Ongoing symptoms may indicate an alternative diagnosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the patient has improved, rechallenge with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , or any formulation containing abacavir (eg, Epzicom), in a patient with suspected AHR is absolutely",
"    <strong>",
"     contraindicated",
"    </strong>",
"    . Rechallenge to abacavir after an initial hypersensitivity reaction can result in a more rapid, severe, and potentially life-threatening reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In the retrospective study discussed above, rechallenge resulted in reappearance of symptoms within hours; hypotension was present in 25 percent of these recurrent reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26\">",
"     26",
"    </a>",
"    ]. Among patients who received abacavir in clinical trials, the mortality rate was 0.03 percent (3 per 10,000 patients).",
"   </p>",
"   <p>",
"    For a diagnostic evaluation to investigate the patient with possible AHR, (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EARLY STUDIES OF IMMUNOGENETIC SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, epidemiologic data demonstrated a strong association between the presence of the HLA-B*5701 allele and a history of AHR. Subsequent observational studies performed in Australia, United Kingdom, France, and North America have demonstrated that immunogenetic screening can significantly reduce the risk of an adverse drug-related hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/17,21-24,39,40\">",
"     17,21-24,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single cohort study of mainly white patients starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      from 2002 to 2005, the incidence of AHR was 2 percent in 151 patients; this rate was much lower than historical controls where 8 percent experienced AHR prior to the introduction of genetic screening [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/21\">",
"       21",
"      </a>",
"      ]. No cases of AHR were described in the 138 HLA-B*5701-negative patients. Genetic screening was also associated with reduction in the clinical overdiagnosis of HSR.",
"     </li>",
"     <li>",
"      In a small study of 137 patients initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , prospective screening led to the absence of any cases of AHR [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large prospective trials have helped to further define the role of immunogenetic screening to prevent AHR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF HLA-B*5701 SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have demonstrated the improved safety of drug administration with prior immunogenetic screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     PREDICT-1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Prospective Randomized Evaluation of DNA Screening in a Clinical Trial (PREDICT-1) was a double-blinded study enrolling 1956 predominantly white patients across 265 European and Australian sites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients were randomly assigned to either prospective or retrospective HLA-B*5701 testing before initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    exposure and followed for six weeks. All patients with a clinical diagnosis of AHR underwent skin patch testing 6 to 10 weeks following AHR diagnosis for immunologic confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/27\">",
"     27",
"    </a>",
"    ]. The primary objective was to test the hypothesis that prospective screening for HLA-B*5701 and the exclusion of patients carrying the allele from abacavir treatment reduces the incidence of hypersensitivity. The study demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 980 patients in the prospective screening group, 55 (6 percent) were excluded from the main study because they were carriers of HLA-B*5701.",
"     </li>",
"     <li>",
"      The incidence of clinically diagnosed hypersensitivity reactions was significantly lower in the prospective screening group than in the control group (3.4 versus 7.8 percent). In addition, no immunologically confirmed cases were diagnosed in the prospective screening group, whereas 2.7 cases occurred in the control group.",
"     </li>",
"     <li>",
"      For immunologically confirmed hypersensitivity reactions, the HLA-B*5701 allele was associated with a positive predictive value of 48 percent and a negative predictive value of 100 percent. For clinically diagnosed cases, the presence of HLA-B*5701 had a positive predictive value of 61 percent and a negative predictive value of 96 percent.",
"     </li>",
"     <li>",
"      100 patients who were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      tolerant had negative skin patch testing for a specificity of 100 percent. By chance, none of these patients were carriers of HLA-B*5701.",
"     </li>",
"     <li>",
"      In a multivariate model, concurrent use of a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor could account for approximately 45 percent of the clinically diagnosed cases of AHR that did not have immunologic confirmation, suggesting that symptom overlap was responsible for a false positive clinical diagnosis of AHR in some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was the first study of its kind to examine the clinical effectiveness of a genetic screening test to prevent a specific drug toxicity. Immunologically confirmed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity, which occurred in 2.7 percent of the control arm, was eliminated in the screened arm, giving a 100 percent negative predictive value for HLA-B*5701 screening. This suggests that HLA-B*5701 is an ideal screening test for the prevention of immunologically confirmed HSR. In contrast, the overall positive predictive value of HLA-B*5701 testing for hypersensitivity reaction to abacavir was 55 percent. This suggests that HLA-B*5701 is necessary, but not sufficient, for the development of AHR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     ARIES trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    <span class=\"nowrap\">",
"     Induction/Simplification",
"    </span>",
"    with Epzicom Study (ARIES) was the first treatment trial to prospectively employ HLA-B*5701 screening in its design [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/17\">",
"     17",
"    </a>",
"    ]. In this study of 725 patients, 5.7 percent were HLA-B*5701-positive. Out of 517 HLA-B*5701-negative individuals enrolled, only four (0.8 percent) were diagnosed with AHR during the study and all four had a negative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    skin patch test performed at least six weeks following the original reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING PRIOR TO ABACAVIR EXPOSURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Whom to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the carriage rate of HLA-B*5701 is low in many nonwhite populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/24\">",
"     24",
"    </a>",
"    ], it has been argued that screening may not be cost-effective in such populations in which the epidemiology of HLA-B*5701 carriage has been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Epidemiology of AHR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, evidence suggests that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 100 percent negative predictive value of screening generalizes across ethnicity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Screening also decreases the 2 to 7 percent false positive clinical diagnosis regardless of ethnicity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/17,21-23,39,40\">",
"       17,21-23,39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Technologies for screening are becoming more feasible as they become less expensive [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, selective screening on the basis of the perceived race or ethnic background of the patient in areas where screening is already available is unlikely to be practical, ethical, or safe because of increasing rates of racial or ethnic admixture and because of the unreliability of the assignment of race or ethnic group by the patient or his or her clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/45\">",
"     45",
"    </a>",
"    ]. The Federal Drug Administration (FDA) has recommended that all patients be informed about the availability of pharmacogenetic testing prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Role of skin patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin patch testing is only useful in patients who have had AHR. It cannot be used as a screening tool since the results of the test depend on prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ingestion and immunologic priming. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the use of HLA-B*5701 screening in clinical practice in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -na&iuml;ve subjects to prevent abacavir hypersensitivity, regardless of race. The DHHS and IAS-USA guidelines endorse the use of abacavir or the fixed-dose coformulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    in patients who have tested negative for HLA-B*5701 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, when HLA-B*5701 testing is not readily available, abacavir may be initiated with appropriate clinical counseling and monitoring for any signs of hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those who are found to have a positive HLA-B*5701 screening test should not be prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and should have this information recorded prominently in their medical records to avoid future exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MONITORING OF PATIENTS ON ABACAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic screening for HLA-B*5701 improves the safety of prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    by ensuring that genetically predisposed individuals are not exposed and sensitized to abacavir. However, appropriate counseling of patients of potential signs and symptoms is still indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical vigilance for hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    will always remain the cornerstone of management, regardless of results of HLA-B*5701 testing, due to the possibility that other rare HLA associations may also exist. Although there have been case reports of possible AHR reported in patients who have screened negative for HLA-B*5701, none of the patients reported have met clinical and immunological criteria for AHR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/23,50\">",
"     23,50",
"    </a>",
"    ]. The appropriate and safe way to find such a second HLA allele is through careful clinical and immunological investigation of HLA-B*5701-negative patients who develop clinical symptoms compatible with AHR. Rechallenge with abacavir should not be performed without appropriate clinical evaluation, including skin patch testing. Clinicians may use the following website for information regarding study of patients with potential AHR:",
"    <a class=\"external\" href=\"file://iiid.murdoch.edu.au/\">",
"     file://iiid.murdoch.edu.au/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING AND QUALITY ASSURANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the implementation of systematized screening efforts, maintenance of robust quality assurance programs will be necessary to maintain a high and consistent standard of laboratory testing.",
"   </p>",
"   <p>",
"    One study distributed DNA panels to seven laboratories for blinded typing of the HLA-B*5701 allele and found excellent concordance and performance (100 percent specificity and 99.4 percent specificity) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/51\">",
"     51",
"    </a>",
"    ]. Currently, the Royal College of Pathologists of Australia is internationally administering a program to ensure consistency of laboratory testing (",
"    <a class=\"external\" href=\"mailto:enrolment@rcpa.com.au\">",
"     enrolment@rcpa.com.au",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Technologies available for HLA-B*5701 screening include not only full high-resolution HLA typing (DNA sequence-based typing), but also PCR-based techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/42,44\">",
"     42,44",
"    </a>",
"    ] and flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/43\">",
"     43",
"    </a>",
"    ] with a monoclonal antibody to",
"    <span class=\"nowrap\">",
"     HLA-B57/58",
"    </span>",
"    (B17). Patients can receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    based on a negative B17 monoclonal antibody test; however, a positive test must be confirmed to be specifically HLA-B*5701 through high resolution HLA typing or a PCR-based HLA-B*5701-specific assay. Flow cytometric techniques are particularly attractive for their potential ease for incorporation in baseline HIV laboratory testing, which already includes CD4+ and CD8+ T cell testing; these techniques may eventually lend themselves to point of care testing in resource-poor settings. High resolution HLA typing has a longer turnaround time, is costly, and is largely restricted to specialty",
"    <span class=\"nowrap\">",
"     immunogenetic/transplant",
"    </span>",
"    laboratories.",
"   </p>",
"   <p>",
"    One group recently advocated the use of HCP5, a HLA-B*5701 haplospecific marker only 100 kb centromeric from HLA-B, as a surrogate screening test for HLA-B*5701. However, clinical and patch test-confirmed AHR has occurred in the setting of HCP5 negativity, suggesting that HLA-B*5701 is necessary for the development of AHR and should remain the gold standard as a genetic screening test for AHR; HCP5 testing cannot be safely applied as a screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;From clinical trial and observational data in a Caucasian population, approximately 13 patients would need to be screened to prevent one case of clinically false positive or true immunologically mediated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity, suggesting that screening is cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/4\">",
"     4",
"    </a>",
"    ]. One analysis suggested that routine testing for HLA-B*5701 appeared to be a cost-effective measure and that overall cost is driven by the treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baseline screening for HLA-B*5701 is likely to be cost-effective in routine HIV practice due to [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The availability of rapid and inexpensive tests for HLA-B*5701 screening",
"     </li>",
"     <li>",
"      The impact of testing on improving the clinical diagnosis of AHR",
"     </li>",
"     <li>",
"      The morbidity associated with AHR, including hospitalization and death, when screening is not employed",
"     </li>",
"     <li>",
"      The negative impact on HIV care when a false clinical diagnosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      hypersensitivity is made and treatment is discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     FUTURE RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, HLA-B*5701 is necessary, but not sufficient, for the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity. Since the positive predictive value of HLA-B*5701 for abacavir hypersensitivity is 55 percent, research is ongoing to identify why 45 percent of patients with HLA-B*5701 can tolerate the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/53\">",
"     53",
"    </a>",
"    ]. The altered peptide repertoire model that explains the basis of abacavir hypersensitivity may apply to other drug hypersensitivity syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21049/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. This should further define HLA-peptide-drug interactions and provides an approach for preclinical screening of drugs for immunological toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      is a nucleoside analog with potent activity against HIV; however, a proportion of patients develop a hypersensitivity reaction to this drug after exposure, which can lead to significant morbidity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A strong body of evidence from both basic science and clinical research has demonstrated that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      hypersensitivity is associated with HLA-B*5701 background and is mediated via CD8+ T-lymphocytes. No HLA allele other than HLA-B*5701 has been associated with immunologically-confirmed abacavir hypersensitivity to date; the mechanistic basis for this exclusivity is based on the specificity of abacavir binding to the HLA-B*5701 molecule. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immunogenetic basis for AHR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the pre-screening era, AHR was diagnosed in 4 to 8 percent of treated patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology of AHR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AHR typically presents with a combination of symptoms, including fever, rash, gastrointestinal disturbances, and other constitutional symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      should be discontinued in a patient with signs and symptoms of AHR that progress without another explanation. Once the patient has improved, rechallenge with abacavir, or any formulation containing abacavir (eg, Epzicom) in a patient with suspected AHR is absolutely contraindicated. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin patch testing helps to define those patients with a history of possible AHR with true immunogenetically-mediated disease versus a false positive clinical diagnosis. Although useful as a research tool in clinical trials, skin patch testing should not be used as the basis for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      rechallenge. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients who are being considered for therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , we recommend HLA-B*5701 screening to decrease the risk of AHR (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This is consistent with recommendations from international guideline committees. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening prior to abacavir exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although genetic screening for HLA-B*5701 improves the safety of prescribing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , appropriate counseling of patients of potential signs and symptoms is still indicated, even if their screening test is negative. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monitoring of patients on abacavir'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/1\">",
"      Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012; 91:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/2\">",
"      Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/3\">",
"      Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/4\">",
"      Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010; 11:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/5\">",
"      Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101:4180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/6\">",
"      Martin AM, Almeida CA, Cameron P, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007; 21:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/7\">",
"      Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/8\">",
"      Almeida CA, Martin AM, Nolan D, et al. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008; 13:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/9\">",
"      Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/10\">",
"      Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012; 109:9959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/11\">",
"      Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/12\">",
"      Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012; 26:F21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/13\">",
"      Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/14\">",
"      Lin JH, Li H, Yasumura D, et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007; 318:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/15\">",
"      Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/16\">",
"      Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/17\">",
"      Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008; 22:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/18\">",
"      Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/19\">",
"      Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/20\">",
"      Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/21\">",
"      Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/22\">",
"      Zucman D, Truchis Pd, Majerholc C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/23\">",
"      Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/24\">",
"      Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/25\">",
"      Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/26\">",
"      Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/27\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/28\">",
"      Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. AIDS 2008; 22:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/29\">",
"      Garc&iacute;a JT, Gonz&aacute;lez PR, Hern&aacute;ndez-Mora MG, et al. Large lymphadenopathies complicating the abacavir hypersensitivity reaction. AIDS 2007; 21:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/30\">",
"      Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 2008; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/31\">",
"      Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 16:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/32\">",
"      DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/33\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/34\">",
"      Keiser P, Nassar N, Skiest D, et al. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS 2003; 14:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/35\">",
"      Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol 2008; 121:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/36\">",
"      Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002; 24:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/37\">",
"      Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read 2001; 11:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/38\">",
"      Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/39\">",
"      Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. Antivir Ther 2006; 11:L11.",
"     </a>",
"    </li>",
"    <li>",
"     Trottier B, Thomas R, Nguyen VK, Machouf N. How effectively HLA screening can reduce the early discontinuation of abacavir in real life. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25, 2007, Sydney, Australia, abstract MOPEB002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/41\">",
"      Abel S, Paturel L, Cabi&eacute; A. Abacavir hypersensitivity. N Engl J Med 2008; 358:2515; author reply 2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/42\">",
"      Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens 2007; 70:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/43\">",
"      Martin AM, Krueger R, Almeida CA, et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/44\">",
"      Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005; 65:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/45\">",
"      Vandekerckhove L, Blot S, Vogelaers D. Abacavir hypersensitivity. N Engl J Med 2008; 358:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/46\">",
"      GSK's Ziagne Relabeled: REMS and the path to personalized medicine. \"The Pink Sheet\" 2008; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on September 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/48\">",
"      Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/49\">",
"      Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008; 42:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/50\">",
"      Bonta PI, Vermeulen JN, Speelman P, Prins JM. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. AIDS 2008; 22:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/51\">",
"      Hammond E, Almeida CA, Mamotte C, et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther 2007; 12:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/52\">",
"      Colombo S, Rauch A, Rotger M, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008; 198:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/53\">",
"      Phillips E, Nolan D, Thorborn D, et al. Genetic factors predicting abacavir hypersensitivity and tolerance in HLA-B*5701 positive individuals. Eur J Dermatol 2008; 18:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21049/abstract/54\">",
"      Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3779 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E002DE631A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21049=[""].join("\n");
var outline_f20_35_21049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMUNOGENETIC BASIS FOR AHR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY OF AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical diagnosis of AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Association of AHR and race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVIDENCE OF LINK BETWEEN HLA BACKGROUND AND AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Carriage rates of HLA-B*5701 and risk of AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Testing performance among different racial populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AVAILABLE TESTING METHODS FOR AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sensitivity and specificity of HLA-B*5701 screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Skin patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EARLY STUDIES OF IMMUNOGENETIC SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL TRIALS OF HLA-B*5701 SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREDICT-1 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ARIES trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING PRIOR TO ABACAVIR EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Whom to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Role of skin patch testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MONITORING OF PATIENTS ON ABACAVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LABORATORY TESTING AND QUALITY ASSURANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      FUTURE RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3779|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/35/3647\" title=\"algorithm 1\">",
"      Screening implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3779|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/30/26084\" title=\"figure 1\">",
"      Crystal structure of the abacavir MHC peptide complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/32/3592\" title=\"figure 2\">",
"      HLAB5701 carriage frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/57/33695\" title=\"figure 3\">",
"      Patch test control diagram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3779|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/36/37444\" title=\"picture 1\">",
"      Positive skin patch test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21050="Use of androgens and other hormones to enhance athletic performance";
var content_f20_35_21050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of androgens and other hormones to enhance athletic performance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/35/21050/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/35/21050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal medications have been used for many years to improve athletic performance. The focus of the general news media is on the athletes who are caught using these medications in popular sporting events, such as the Olympics, baseball, and the Tour de France bicycle race [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/1\">",
"     1",
"    </a>",
"    ]. However, recreational athletes also use these medications, and less often others use them to improve overall strength and appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus on the epidemiology, physical effects, and adverse effects of hormones used to improve athletic performance and physical appearance. The use of non-hormonal agents is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=see_link\">",
"     \"Non-hormonal performance enhancement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of androgens has spread from competitive sports to leisure and fitness sports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Bodybuilders and non-athletes use androgens as a strategy to increase muscle mass and physical attractiveness. The frequency of this use of drugs by athletes and non-athletes has been addressed in a number of studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2009, the United States Anti-Doping Agency (USADA) reported performing over 8000 tests in Olympic, Paralympic, and Pan American sports; 26 potential doping cases were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is estimated that approximately 1 percent of the entire population in the US and Sweden use androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one US survey, nearly four out of five users of androgens were recreational athletes and body builders [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, 1 out of 10 users reported hazardous injection techniques, including sharing needles.",
"     </li>",
"     <li>",
"      In 2011, the Centers for Disease Control (CDC) reported that 3.6 percent of high school students had taken androgenic steroids without a doctor's prescription at least once [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/6\">",
"       6",
"      </a>",
"      ]. Among students nationwide, the prevalence increased during 1991 to 2003 (from 2.7 to 6.1 percent) and then decreased between 2003 and 2011 (from 6.1 to 3.6 percent).",
"     </li>",
"     <li>",
"      Most adolescent steroid users are boys. In 2009, the Monitoring the Future Survey of the National Institute of Drug Abuse reported that 1.0, 1.2, and 2.5 percent of 8",
"      <sup>",
"       th",
"      </sup>",
"      , 10",
"      <sup>",
"       th",
"      </sup>",
"      , and 12",
"      <sup>",
"       th",
"      </sup>",
"      grade boys, respectively, had used steroid drugs during the previous year. Rates were lower in girls (0.5, 0.4, and 0.4 percent for 8",
"      <sup>",
"       th",
"      </sup>",
"      , 10",
"      <sup>",
"       th",
"      </sup>",
"      , and 12",
"      <sup>",
"       th",
"      </sup>",
"      grade girls, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lifetime prevalence of use in high school girls in the CDC survey was 2.9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth hormone, like androgens, has been linked to many prominent athletes in sports such as baseball, swimming, and cycling [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, approximately 5 percent of US high school students report using growth hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Growth hormone'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of these medications is more common when there is a family or personal history of drug abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/9\">",
"       9",
"      </a>",
"      ], and in sports where use is more prevalent, such as cycling, baseball, and weightlifting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606912358\">",
"    <span class=\"h2\">",
"     Patterns of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;As most athletes who take androgens or other agents to improve athletic performance do so surreptitiously, the pattern of use differs substantially from that of other",
"    <span class=\"nowrap\">",
"     medications/drugs:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Users",
"      often obtain the drugs from sources other than clinicians. Some will use drugs intended for veterinary purposes or obtain substances from laboratories that are not regulated by government agencies for manufacturing quality.",
"     </li>",
"     <li>",
"      Some users will take more than the prescribed dose or will use medications prescribed for others.",
"     </li>",
"     <li>",
"      Athletes often take performance-enhancing drugs in various patterns, including in escalating doses (\"pyramiding\"), consecutively (\"stacking\"), simultaneously, intermittently, or cyclically, in an attempt to increase the overall effect on performance and the latter to avoid detection.",
"     </li>",
"     <li>",
"      Users may attempt to counter a side effect of one medication with another medication. As examples, an athlete might take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"       human chorionic gonadotropin",
"      </a>",
"      (hCG) to counteract the reduction in testicular size resulting from high-dose androgen use, take an aromatase inhibitor to counteract gynecomastia from high doses of hCG, or take a 5-alpha reductase inhibitor to prevent balding and acne that occur with exogenous androgens.",
"     </li>",
"     <li>",
"      Athletes discontinue the medications periodically to avoid side effects and detection just before a competition.",
"     </li>",
"     <li>",
"      Rather than asking a clinician, users may seek information about performance-enhancing drugs from athletes, trainers, magazines, underground publications, and the internet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606912732\">",
"    <span class=\"h2\">",
"     Banned drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past decade, the list of drugs banned by the World Anti-Doping Agency (WADA) has grown to over 100 (",
"    <a class=\"graphic graphic_table graphicRef69779 \" href=\"UTD.htm?12/46/13025\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/10\">",
"     10",
"    </a>",
"    ]. The 2011 WADA list includes androgens, &ldquo;peptide hormones, growth factors and related substances,&rdquo; hormone antagonists and modulators, diuretics and other masking agents, stimulants, narcotics, cannabinoids, alcohol, glucocorticoids, beta-agonists, and beta-blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/11\">",
"     11",
"    </a>",
"    ]. It also includes different prohibited methods of enhancement including oxygen transfer, chemical and physical manipulation, and gene doping. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=see_link\">",
"     \"Non-hormonal performance enhancement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians caring for competitive athletes should be aware of doping regulations, as some banned drugs may be taken for medical purposes (eg, beta-blockers, diuretics, 5-alpha-reductase inhibitors) (",
"    <a class=\"graphic graphic_table graphicRef69779 \" href=\"UTD.htm?12/46/13025\">",
"     table 1",
"    </a>",
"    ). Although athletes are responsible for informing clinicians that they are subject to doping restrictions, they may not realize that they are taking a substance that is prohibited. Clinicians should consider reviewing drug",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplement use to determine if an athlete is taking a banned substance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANDROGENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types of androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all androgens produced for human or veterinary purposes have been taken by athletes (",
"    <a class=\"graphic graphic_figure graphicRef53955 \" href=\"UTD.htm?15/21/15699\">",
"     figure 1",
"    </a>",
"    ). These include testosterone esters, which are usually taken by injection, the 17-alpha-alkylated androgens, which are usually taken orally, and androgen precursors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909518\">",
"    <span class=\"h3\">",
"     Exogenous testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The testosterone esters include the enanthate and cypionate, which are also used for hormone replacement. Testosterone preparations for clinical use are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H3#H3\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Testosterone preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909511\">",
"    <span class=\"h3\">",
"     Synthetic androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic steroidal androgens, eg, oral 17-alpha-alkylated androgens (eg, stanozolol) or parenteral 19-nortestosterone derivatives (eg, nandrolone), were originally developed to have a greater anabolic to androgenic effect than testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/12\">",
"     12",
"    </a>",
"    ]. They were therefore given the name \"anabolic steroids,\" which persists today. However, whether these compounds have a higher ratio of anabolic to androgenic activity than testosterone in humans is uncertain. Although there is only one androgen receptor, which is present in many tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/13\">",
"     13",
"    </a>",
"    ], there are many cofactors that influence the transcriptional activity of the androgen receptor. These factors, called coactivators or corepressors, differ from tissue to tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/14\">",
"     14",
"    </a>",
"    ], and provide a theoretical basis for a compound to affect the androgen receptor differently in one tissue compared to another. Nevertheless, no compound has yet been found to have a greater anabolic effect than androgenic effect in humans, and therefore they will all be referred to here simply as androgens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Androgen precursors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The androgen precursors include androstenedione and dehydroepiandrosterone (DHEA).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androstenedione is widely used and promoted in bodybuilding magazines. Until 2004, products containing androstenedione (&ldquo;andro&rdquo;) were available as over-the-counter nutritional supplements. However, in October 2004 the Anabolic Steroid Control Act classified androstenedione (and 17 other steroids) as controlled substances with significant health risks. As of January 2005, these substances may not be sold without a prescription [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Androstenedione does not appear to have an anabolic effect like testosterone, and its effect on serum androgens is variable (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      below). Administration of 300 mg of androstenedione once daily for one week to normal young men increased their mean serum testosterone concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/16\">",
"       16",
"      </a>",
"      ], but administration of 100 mg three times a day for eight weeks did not [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/17\">",
"       17",
"      </a>",
"      ]. In a third study, in which 100 mg of androstenedione or placebo was given to normal men three times a day in a double-blind fashion for four weeks, the total testosterone concentration did not increase in the androstenedione-treated men, but free testosterone (measured by an analog assay, which may not be accurate), dihydrotestosterone, and estradiol did [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DHEA is also available as a \"nutritional supplement\" and is widely touted in body building magazines as an agent that will increase muscle strength. It is not androgenic itself, but is converted to testosterone. However, in three trials of administration of DHEA to normal young men, the serum concentration of DHEA increased, but that of testosterone did not [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. The effect of DHEA on strength is reviewed below, and other uses of DHEA are discussed separately. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=see_link\">",
"       \"Dehydroepiandrosterone and its sulfate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606910564\">",
"    <span class=\"h3\">",
"     SARMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective androgen receptor modulators (SARMs) are nonsteroidal, orally active molecules developed to bind better to androgen receptors in certain tissues, such as muscle and bone, than to those in genital tissue with the goal of improving muscle weakness, osteoporosis, and other conditions with less risk of worsening prostate diseases in men or causing virilization in women. Although none of these compounds have been approved for use in humans in any country, a doping laboratory in Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/22\">",
"     22",
"    </a>",
"    ] obtained a vial of the SARM Andarine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/23\">",
"     23",
"    </a>",
"    ] via the Internet, indicating that at least one of these compounds is available for abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909468\">",
"    <span class=\"h3\">",
"     Other forms of androgen stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to increasing endogenous testosterone concentrations is by taking exogenous hCG, antiestrogens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , or aromatase inhibitors. These drugs result in an increase in serum testosterone concentrations, and all are banned by the World Anti-Doping Agency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H606910333\">",
"     'Estrogen blockade'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911831\">",
"    <span class=\"h4\">",
"     Use of hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    (hCG), which binds to the luteinizing hormone (LH) receptor and stimulates the Leydig cells of the testes to secrete testosterone, has also been used by athletes. hCG leads to production of endogenous testosterone in the normal ratio to epitestosterone, making its use more difficult to distinguish from normal secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/24\">",
"     24",
"    </a>",
"    ]. Luteinizing hormone has a very short half-life and is not likely to be abused.",
"   </p>",
"   <p>",
"    Side effects of hCG include edema and gynecomastia. Detection of hCG is discussed below. (See",
"    <a class=\"local\" href=\"#H606910879\">",
"     'hCG'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It seems intuitive that androgens increase muscle mass and muscle strength, given the obvious differences between men and women. Administration of supraphysiologic doses of exogenous testosterone to healthy young men has been shown to increase their muscle strength. However, there is no evidence that the androgen precursor, androstenedione, increases muscle strength, and the evidence for an effect of DHEA is conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one placebo-controlled, double-blind study of exogenous testosterone, 43 normal men were randomly assigned to one of four groups: strength training exercise with either 600 mg of testosterone enanthate once per week (about six times a replacement dose) or with placebo; or no exercise with either testosterone or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/25\">",
"       25",
"      </a>",
"      ]. Testosterone treatment increased fat-free mass and muscle strength, both in men who exercised and in men who did not, but more so in those who exercised simultaneously.",
"     </li>",
"     <li>",
"      In a second, double-blind trial of exogenous testosterone, 61 healthy eugonadal men were randomly assigned to one of five groups, each treated with a GnRH agonist to suppress endogenous testosterone secretion and one of five weekly doses of testosterone enanthate from 25 to 600 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/26\">",
"       26",
"      </a>",
"      ]. Testosterone administration was associated with a dose-dependent increase in leg press strength and leg power. Improvements in strength and power correlated with serum total testosterone concentrations. Muscle fatigability did not change with treatment. In contrast, in a randomized, placebo-controlled trial of androstenedione in normal men, administration of 100 mg three times daily for eight weeks did not increase muscle strength; however, serum testosterone concentrations were not increased by this regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/17\">",
"       17",
"      </a>",
"      ]. Similarly, in a placebo-controlled study of 50 healthy men ages 35 to 65 years receiving androstenedione or androstanediol (200",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      neither hormone altered body composition or muscle strength compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Results from placebo-controlled studies of DHEA in normal men have been mixed. In one study in which 40 trained men were given DHEA (100",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      androstenedione, or placebo, there were no differences in fat-free mass and muscle mass between the two drug groups and the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/20\">",
"       20",
"      </a>",
"      ]. In another trial, nine men and 10 women were randomized to receive 100 mg of DHEA or placebo daily for six months and then crossed over for another six months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/21\">",
"       21",
"      </a>",
"      ]. In the men, but not the women, knee and lumbar back strength increased during DHEA treatment compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;All androgens have some side effects when taken in high doses; other side effects depend upon the structure of the androgen or the steroids it is converted to. Some side effects occur only in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911486\">",
"    <span class=\"h3\">",
"     Reproductive",
"    </span>",
"    &nbsp;&mdash;&nbsp;All androgens suppress gonadotropin secretion and therefore in men suppress endogenous testicular function, both testosterone and sperm production. Spermatogenesis and fertility are greatly diminished by exogenous androgens. The sperm count usually returns to normal within four months after discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/28\">",
"     28",
"    </a>",
"    ], but may take more than a year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/29\">",
"     29",
"    </a>",
"    ]. Testicular size may decrease if androgen administration continues for many years. Gonadotropin and testosterone secretion remain suppressed for a few months after androgens are discontinued.",
"   </p>",
"   <p>",
"    Gynecomastia occurs because testosterone is converted to estradiol via the action of the aromatase enzyme complex, so that high doses of testosterone result in high serum estradiol concentrations. Androgens that have been 5 alpha-reduced, such as dihydrotestosterone, and synthetic androgens in which the A ring has been modified, cannot be aromatized and therefore cannot be converted to estrogens and do not cause gynecomastia.",
"    <br/>",
"   </p>",
"   <p>",
"    Pharmacologic doses of testosterone or other androgens that can be aromatized to estrogens hasten epiphyseal closure in adolescents whose epiphyses have not yet closed. The frequency of androgen use in adolescents is discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In women, side effects of androgens include acne, hirsutism, temporal hair recession in a male pattern, clitoromegaly, and deepening of the voice, which is irreversible. Although not well studied, many women also develop oligomenorrhea or amenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911084\">",
"    <span class=\"h3\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of high doses of androgens on cardiac function is uncertain. Several case reports describe sudden death in young athletes who had no previously known heart disease but who were taking androgens; cardiac hypertrophy or myocarditis were found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It is not possible to establish causality in these sporadic cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also reports of left ventricular hypertrophy in body builders and power lifters, but most of these studies have not been randomized or controlled for degree of exercise, which itself can affect the degree of cardiac hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/32\">",
"     32",
"    </a>",
"    ]. In one randomized, placebo-controlled trial, eight body builders treated with nandrolone decanoate showed no difference in several echocardiographic parameters at the end of eight weeks from those treated with placebo, but this study was limited by the small numbers of subjects and short duration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606914355\">",
"    <span class=\"h3\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although physiologic doses of testosterone have no consistent effects on serum lipid concentrations, pharmacologic doses of androgens, especially 17-alpha-alkylated androgens administered orally, decrease serum high-density-lipoprotein (HDL) cholesterol and increase low-density-lipoprotein (LDL) cholesterol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of normal men aged 30 to 56 years given androstenedione (300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 28 days), serum HDL cholesterol concentrations decreased by 15 percent, a change that, in the general population, would predict an increase in risk of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606914362\">",
"    <span class=\"h3\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen administration is associated with activation of the hemostatic system, as illustrated in a study of 49 weight lifters in whom androgen use was ascertained by history and urine testing. The confirmed steroid users had a higher percentage of abnormally high thrombin&ndash;antithrombin complexes in plasma than nonusers (16 versus 6 percent, p = 0.01), higher plasma concentrations of prothrombin fragment 1 (44 versus 24 percent, p&lt;0.001), antithrombin III (22 versus 6 percent, p = 0.005), and protein S (19 versus 0 percent), and lower plasma concentrations of tissue plasminogen activator and its inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/35\">",
"     35",
"    </a>",
"    ]. The importance of hemostatic system activation with regard to risk of thrombosis is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911092\">",
"    <span class=\"h3\">",
"     Neuropsychiatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many psychological abnormalities have been described, both in the medical literature and anecdotally, in men taking high doses of androgens. Most descriptions are uncontrolled, although in one study an attempt was made to compare men taking and not taking androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/36\">",
"     36",
"    </a>",
"    ]. One hundred sixty men recruited from gyms responded to a questionnaire about androgen use and psychiatric symptoms. Psychiatric symptoms, including major mood disorders and aggressive behavior, were more common in the men who had taken androgens than in those who had never taken androgens, and among the former the symptoms were more common when they were taking androgens. Controlled studies using supraphysiologic doses of testosterone enanthate, although lower than those athletes often use, for up to six months demonstrate no [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/25,37,38\">",
"     25,37,38",
"    </a>",
"    ] or minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/39\">",
"     39",
"    </a>",
"    ] psychological abnormalities.",
"   </p>",
"   <p>",
"    Several studies describe an association between nonmedical use of androgens and risky or even criminal behavior. In mail surveys of approximately 10,000 to 15,000 college students from 1993 to 2001, nonmedical use of androgens was associated with cigarette smoking, other illicit drug use, drinking and driving, and DSM-IV alcohol use disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of data from the Longitudinal Study of Adolescent Health, in which 6823 adolescents surveyed on three occasions between 7",
"    <sup>",
"     th",
"    </sup>",
"    and 12",
"    <sup>",
"     th",
"    </sup>",
"    grades, demonstrated that nonmedical use of androgens was associated with violent behavior, such as physical fighting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who use anabolic steroids have described both hypomanic and depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In addition, some women report rigid dietary practices (referred to as &ldquo;eating disorder, bodybuilder type&rdquo;), nontraditional gender roles, and",
"    <span class=\"nowrap\">",
"     dissatisfaction/preoccupation",
"    </span>",
"    with their bodies (referred to as &ldquo;muscle dysphoria&rdquo;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Erythrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone stimulates erythropoiesis, and in men made hypogonadal by administration of a GnRH agonist, increases hemoglobin and hematocrit in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/44\">",
"     44",
"    </a>",
"    ]. Erythrocytosis is a well-recognized side effect of treatment of hypogonadism with physiologic doses of testosterone. Erythrocytosis, sometimes to a severe degree, has also been reported in association with administration of pharmacologic doses of androgens, but only in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic side effects occur only with oral 17-alpha-alkylated androgens and include high serum concentrations of liver enzymes, cholestatic jaundice, and peliosis hepatitis, characterized by blood-filled hepatic cysts. Hepatomas have also been reported, but the number of cases is few and causality is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H4#H4\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Alkylated androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic case reports describe infections due to injection of androgens, including local abscess at the site of injection, septic arthritis, hepatitis B and C, and HIV infection from sharing of needles [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273222414\">",
"    <span class=\"h3\">",
"     Prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the prostate is a testosterone-dependent gland, there is concern that the high doses of androgens that athletes take might increase the risk of benign prostatic hypertrophy and prostate cancer. A meta-analysis of replacement doses of testosterone in hypogonadal men did not show such increased risks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/47\">",
"     47",
"    </a>",
"    ], but the risk in athletes who take large doses of androgens has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493467\">",
"    <span class=\"h3\">",
"     Tendon rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of tendons (such as the triceps or biceps tendon) has been reported in weight lifters who use androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Detection of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous administration of pharmacologic doses of androgens might be suspected in a man who competes in a sport in which excess androgens are perceived as improving performance and who have small testes, low sperm counts, high hematocrit and hemoglobin values, and low serum sex hormone-binding globulin concentrations. In a woman, androgen abuse might be suspected in an athlete with hirsutism, balding, or acne. In both genders, androgen abuse might be suspected in those who appear excessively muscular. Androgen use can be detected in such patients by one of several tests, depending upon the compound to be tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909324\">",
"    <span class=\"h3\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Anti-Doping Agency (WADA) utilizes two main methods for detecting testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Testosterone/epitestosterone",
"      </span>",
"      ratio &ndash; Testosterone taken exogenously cannot be distinguished from that produced endogenously by the usual methods for measuring testosterone radioimmunoassay and tandem mass spectroscopy, so other methods must be used. The conventional method is to determine the urinary ratio of testosterone glucuronide to its endogenous epimer, epitestosterone glucuronide",
"      <span class=\"nowrap\">",
"       (T/E",
"      </span>",
"      ratio). Normally the ratio is 1 to 3:1, but subjects taking exogenous testosterone, which suppresses the production of both testosterone and epitestosterone and replaces it only with testosterone, have higher ratios, usually &gt;6:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/51\">",
"       51",
"      </a>",
"      ]. However, a",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio of &gt;4:1 is considered evidence of doping by the World Anti-Doping Agency (WADA).",
"      <br/>",
"      <br/>",
"      The limitation of the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio is shown by the much greater between, than within, subject variability [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/52\">",
"       52",
"      </a>",
"      ]. The reason for this difference has been shown to result from heterozygosity in the uridine diphosphoglucuronosyl transferase that converts testosterone to testosterone glucuronide (",
"      <a class=\"graphic graphic_figure graphicRef50268 \" href=\"UTD.htm?4/21/4447\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/53\">",
"       53",
"      </a>",
"      ]. No such heterozygosity apparently exists in the glucuronosyl transferase that converts epitestosterone to epitestosterone glucuronide. The consequence is that a man who has a deletion of both copies of this enzyme converts testosterone to testosterone glucuronide poorly, so after an injection of exogenous testosterone, his",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio is much lower than a man who has two copies of the gene. This deletion is more common in Asians than Caucasians [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/54\">",
"       54",
"      </a>",
"      ]. Conventional monitoring by this ratio, therefore, is much less likely to detect the athlete who has both copies deleted and who takes exogenous testosterone than the athlete who has two normal copies of the gene (",
"      <a class=\"graphic graphic_figure graphicRef50268 \" href=\"UTD.htm?4/21/4447\">",
"       figure 2",
"      </a>",
"      ). The investigators who elucidated this heterozygosity proposed setting normal ranges for the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio depending on whether or not the athlete has two, one, or no copies of this gene. In addition, some single nucleotide polymorphisms in the promoter region of the CYP17 gene are associated with higher",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio, which may explain why some normal individuals have naturally high",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratios in the absence of androgen abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/55\">",
"       55",
"      </a>",
"      ]. Another limitation of the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio is that athletes can mask testosterone use by taking gonadotropins or epitestosterone, which can reduce the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The method currently considered most accurate is determination of the ratio of carbon 13 (13C) to carbon 12 (12C) in urinary metabolites of testosterone using isotope ratio mass spectrometry. The rationale is that pharmacologic testosterone preparations are synthesized from plant sterols, which have a lower ratio of 13C to 12C than do endogenous testosterones [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/57\">",
"       57",
"      </a>",
"      ]. This method will show a low 13C to 12C ratio even if an athlete takes epitestosterone in an attempt to mask taking testosterone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, suspicion for exogenous testosterone use should be high in an athlete with a normal or elevated testosterone:epitestosterone ratio and low 13C to 12C ratio. These tests are offered by official testing bodies but not clinically. Offering them outside of the official process would alert those taking androgens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909380\">",
"    <span class=\"h3\">",
"     Other androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens other than testosterone can be detected by gas chromatography and mass spectometry if the athlete is still taking the compound(s) at the time of testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/50\">",
"     50",
"    </a>",
"    ]. These tests are usually performed at commercial laboratories. Androgens other than testosterone also cause a high",
"    <span class=\"nowrap\">",
"     T/E",
"    </span>",
"    ratio since androgens suppress endogenous testosterone production.",
"   </p>",
"   <p>",
"    Selective androgen receptor modulators (SARMs) can be detected in urine. This detection can be accomplished through solid-phase extraction followed by liquid chromatography-tandem mass spectrometry utilizing electrospray ionization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606910879\">",
"    <span class=\"h3\">",
"     hCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;hCG can be detected by immunoextraction of urine and mass spectrometry. The proposed male cutoff is 5",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    Because hCG is elevated in patients with testicular cancer, it may be a false positive for doping in this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/56\">",
"     56",
"    </a>",
"    ]. There are privacy implications when testing urinary hCG in women, as the test is also used to detect pregnancy. LH use can be determined by urine immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606912472\">",
"    <span class=\"h2\">",
"     Avoiding detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes are continually finding ways to avoid detection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/58\">",
"     58",
"    </a>",
"    ]. The most common way is to discontinue the drug before testing will occur. Screening tests can also be manipulated by urine substitutes, urine dilution, refusing to provide samples of urine or blood, and placing substances in the urethra to mask the samples. As an example, athletes may concomitantly take diuretics and increase fluid intake to dilute urine. Some substances have protease activity, and there should be a high level of suspicion in the absence of urinary proteins in a sample.",
"   </p>",
"   <p>",
"    Other indicators of sample tampering include urine at room temperature from a newly-obtained sample or specific gravity out of the range of normal. If the screening tests detect abnormal results, typically more advanced techniques such as liquid chromatography and mass spectrometry are used to confirm the results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/3,59\">",
"     3,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one highly publicized case, a private laboratory synthesized an androgenic steroid specifically designed to avoid detection. The drug was identified when a syringe filled with it was provided to the United States Anti-Doping Agency, which eventually determined that the drug was tetrahydrogestrinone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606909303\">",
"    <span class=\"h2\">",
"     Therapeutic use exemption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World and the US Anti-Doping Agencies allow athletes to compete if they are taking a banned medication because they need it medically. In this situation, they grant a Therapeutic Use Exemption (TUE) after reviewing a TUE form completed by the athlete's clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/61\">",
"     61",
"    </a>",
"    ]. The clinician must state that the athlete would experience a significant health problem if he did not take the prohibited medication, the medication would not produce significant enhancement of performance, and there is no reasonable therapeutic alternative. An example is an athlete who takes testosterone because he has had bilateral orchiectomy for testicular cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606910333\">",
"    <span class=\"h1\">",
"     ESTROGEN BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen blockade with drugs that block estrogen action or synthesis is another strategy for raising serum testosterone levels in men. They are also sometimes coadministered with androgens to prevent gynecomastia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of gynecomastia\", section on 'Drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs in this category include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4121017\">",
"    <span class=\"h2\">",
"     Antiestrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiestrogens bind to and block the estrogen receptor. The original antiestrogens included the nonsteroidal drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . These drugs are also referred to as selective estrogen receptor modulators (SERMs); they have estrogen agonist properties in some tissues and estrogen antagonist properties in others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606910666\">",
"    <span class=\"h2\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors are steroidal or nonsteroidal agents that block the conversion of androgens to estrogen. Examples include androstenedione analogs such as testolactone, and the nonsteroidal agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    . They are used to reduce the development of gynecomastia and to attempt to elevate the serum testosterone concentration. Modest elevations of serum testosterone are seen with aromatase inhibitor use in men, but an effect on muscle strength has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/62\">",
"     62",
"    </a>",
"    ]. There are sensitive assays available to detect aromatase inhibitors and antiestrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/50\">",
"     50",
"    </a>",
"    ]. These can be detected in urine by gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectometry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone, like androgens, has been linked to many prominent athletes in sports including baseball, swimming, and cycling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, approximately 5 percent of US high school students use growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/3\">",
"     3",
"    </a>",
"    ]. Growth hormone use by high school athletes in Germany is lower (0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911755\">",
"    <span class=\"h2\">",
"     Physical effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    because of its demonstrated effects on body composition (more muscle, less fat) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/65\">",
"     65",
"    </a>",
"    ]. In earlier studies, growth hormone administration was not shown to be effective for either strength [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] or endurance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study to date in recreational athletes, men were randomly assigned to receive placebo, growth hormone (2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    subcutaneously), testosterone (250",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    intramuscularly), or combined treatments, while women were randomly assigned to receive either placebo or growth hormone (2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/69\">",
"     69",
"    </a>",
"    ]. In both men and women, growth hormone significantly reduced fat mass, increased lean body mass through an increase in extracellular water, and improved sprint capacity, but not strength, power, or endurance. The improvement in sprint capacity was greater when growth hormone was coadministered with testosterone to men. The effects of growth hormone disappeared after six weeks of being discontinued. The clinical significance of the increase in one physical performance parameter but not others in spite of supraphysiologic doses of both drugs is uncertain.",
"   </p>",
"   <p>",
"    Growth hormone would be expected to cause acromegaly if given in high doses long enough, but no such cases have been reported. Another potential concern is cancer, as epidemiologic data suggest an association between serum concentrations of insulin-like growth factor I (IGF-I) and cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H23#H23\">",
"     \"Risk factors for prostate cancer\", section on 'Insulin and insulin-like growth factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of studies in which growth hormone was administered to normal men and women showed an increased incidence of soft tissue edema compared with those not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911809\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone can cause insulin resistance, hyperglycemia, diabetes, sodium retention, hypertension, cardiomegaly, premature epiphyseal closure, myopathy, carpal tunnel syndrome, and swelling of the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8,70,71\">",
"     8,70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H22#H22\">",
"     \"Growth hormone deficiency in adults\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weightlifters who abuse growth hormone were found to have a high use of other risky drugs, such as opioids, cocaine, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/72\">",
"     72",
"    </a>",
"    ], similar to men who abuse androgens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911629\">",
"    <span class=\"h2\">",
"     Detection methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of growth hormone can occur only through the blood because less than 0.1 percent is excreted through urine. Two methods have been proposed to detect use of growth hormone by athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markers of growth hormone action, such as IGF-I and N-terminal extension peptide of procollagen type III (P-III-P) &mdash; One study showed that when growth hormone in doses of 0.033 or 0.066",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      body was administered daily for four weeks to normal men and women, their serum concentrations of IGF-I and P-III-P were readily distinguishable from subjects administered placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/74\">",
"       74",
"      </a>",
"      ]. These effects were shown in a subsequent study to be greater in men than in women and to be increased by concomitant testosterone administration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth hormone isoforms &mdash; The pituitary gland normally secretes a variety of growth hormone isoforms, including a 20 kDa form and a 22 kDa form in monomers and dimers. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      (rhGH) consists only of the 22 kDa monomer. Immunoassays have been developed that can recognize either the 22 kDa form selectively or all of the isoforms nonselectively. Since administration of rhGH suppresses endogenous growth hormone secretion, an elevated ratio of the selective 22 kDa assay to growth hormone measured by the nonselective assay indicates administration of exogenous rhGH [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/73\">",
"       73",
"      </a>",
"      ]. The first athlete detected using this test, a British rugby player, was reported in 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606910688\">",
"    <span class=\"h2\">",
"     Growth factors: IGF-I and insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of insulin-like growth factor (IGF-I) and insulin use for performance enhancement is lower than growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"     8",
"    </a>",
"    ]. Insulin-like growth factor-I (IGF-I) should have similar effects to growth hormone, but this has not been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"     8",
"    </a>",
"    ]. Athletes have also begun to use insulin, in particular, short-acting insulins, because of their anabolic effects on muscle.",
"   </p>",
"   <p>",
"    Insulin and IGF-I may lead to hypoglycemia. In one survey of 20 men who were recruited from gyms and admitted to using androgens, five reported that they also used insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/77\">",
"     77",
"    </a>",
"    ]. They reported ingesting large amounts of sugar after insulin injection to avoid hypoglycemia. Serum concentrations of insulin-like growth factor I (IGF-I) may be associated with an increased risk of prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H23#H23\">",
"     \"Risk factors for prostate cancer\", section on 'Insulin and insulin-like growth factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IGF-I can only be detected through blood. However no commercial screen tests are available at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"     8",
"    </a>",
"    ]. Detection of insulins can be done in the urine with use of",
"    <span class=\"nowrap\">",
"     antibody/antigen",
"    </span>",
"    reactions and liquid",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectometry. However, it is often difficult to distinguish between human insulin, insulin analogs, and porcine insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1353812\">",
"    <span class=\"h1\">",
"     METHODS TO INCREASE OXYGEN TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes have used methods to increase the oxygen-carrying capacity of the blood and thereby athletic performance for decades, initially by training at high altitudes, then by transfusions, and more recently by hypoxia and administration of drugs that stimulate erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/78\">",
"     78",
"    </a>",
"    ]. Use of these methods in competitive cycling, such as the Tour de France, has been reported widely in the popular press. All increase oxygen transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1353819\">",
"    <span class=\"h2\">",
"     Erythropoiesis-stimulating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first available agent was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    , and later",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    , which has a longer half-life. Erythropoietin increases the blood&rsquo;s maximum capacity to transport and utilize oxygen, thereby augmenting aerobic power and physical exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/70,78,79\">",
"     70,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1415409\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxia and hypoxia mimetics &ndash; Training at high altitudes has generally been replaced by induction of hypoxia and administration of drugs that mimic hypoxia, such as the iron chelator desferrioxamine and cobalt. All of these stimulate endogenous erythropoietin production and thereby stimulate erythropoiesis.",
"     </li>",
"     <li>",
"      Transfusion &ndash; This directly increases circulating erythrocytes and, if the transfusion is autologous, decreases the chance of detection.",
"     </li>",
"     <li>",
"      Artificial oxygen carriers &ndash; These include hemoglobin-based oxygen carriers and perfluorocarbons [",
"      <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/80\">",
"       80",
"      </a>",
"      ], first developed as blood substitutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76826127\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major adverse effects of increased erythropoiesis include myocardial infarction, stroke, and thromboembolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/78\">",
"     78",
"    </a>",
"    ]. It may also lead to hypertension, antibody-mediated anemia, and polycythemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H10#H10\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76825861\">",
"    <span class=\"h2\">",
"     Detection methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are indirect and direct methods for detecting erythropoietin. Indirect methods include measurement of total hemoglobin mass, which can increase approximately 10 percent with erythropoietin use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/78,80\">",
"     78,80",
"    </a>",
"    ]. Hematocrit and reticulocyte counts may also increase. Erythropoietin can also be detected directly by immunoaffinity chromatography, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), isoelectric focusing, and mass spectrometry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/58\">",
"     58",
"    </a>",
"    ]. Some users of erythropoietin add proteases in their urine to degrade it [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/78\">",
"     78",
"    </a>",
"    ], but protease inhibitors added to the urine immediately after collection can prevent degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/81\">",
"     81",
"    </a>",
"    ], and specific patterns of degradation suggest their use. Testing is not as well developed for other agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some athletes take several other drugs and supplements in addition to androgens, growth hormone, and erythropoiesis-stimulating agents to enhance performance. Examples include stimulants, creatine, and beta blockers. Non-hormonal performance enhancing agents are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=see_link\">",
"     \"Non-hormonal performance enhancement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606911964\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient admits to using a drug to enhance athletic performance or if these substances are detected by testing, the clinician should attempt to educate the patient on the risks of continued use, although most patients who take these drugs think that they know more about them than do the clinicians. If the performance-enhancing drug is illicit, the clinician is not legally obligated to report, even if the patient is a minor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    A clinician can be found guilty of anti-doping violations for prescribing banned substances to enhance athletic performance, but is not likely to be held responsible for administering a banned drug for medical treatment. Sports organizations may not be sympathetic and can administer harsh suspensions or penalties to an athlete for doping infringements, even if taking a banned substance for an urgent condition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/82\">",
"     82",
"    </a>",
"    ]. Due to difficulties in proving intent to cheat, the World Anti-Doping Agency (WADA) enforces strict liability for positive test results. Clinicians may be asked by an athlete to complete therapeutic use exemption forms prior to sports competitions in order to enable athletes to take WADA-banned substances that are required for medical treatment.",
"   </p>",
"   <p>",
"    When a sports organization identifies a positive screening test in an athlete, it will take further action according to the laws of the country where the testing occurred. These organizations may issue fines and bans from participation in future events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606912021\">",
"    <span class=\"h2\">",
"     Stopping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who take hormones, especially androgens, to enhance athletic performance are usually reluctant to stop, even when they no longer are engaged in the activity for which they took the drugs originally. However, if a man does not ask for advice about stopping, a clinician should encourage him to do so but advise him that he will likely become hypogonadal for a period, perhaps many months, before his pituitary-testicular axis recovers. Such men often ask clinicians for hCG or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    to hasten this process, but there is no evidence that either does so. The clinician should also offer to follow the recovery by measuring the serum testosterone concentration, initially three months after discontinuation of the drug and, if the value is not normal then, periodically thereafter. If fertility is desired, sperm density should be tested, as well, also beginning at three months. Clinicians should be warned, however, that some men say they want to stop taking androgens as an excuse to get a prescription for hCG. When the clinician does not prescribe hCG, they do not return.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12224280\">",
"    <span class=\"h1\">",
"     ROUTINE SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force found insufficient evidence to recommend for or against routine screening for drug abuse in adolescents, including abuse of anabolic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/83\">",
"     83",
"    </a>",
"    ]. The American Academy of Family Physicians, American Medical Association Guidelines for Adolescent Preventive Services, and the American Academy of Pediatrics all suggest that clinicians discuss the dangers of drug abuse with children and adolescents and include questions about substance abuse as a part of routine adolescent visits. Clinicians may also suspect abuse of androgens in adolescents who have problem behavior (eg, fighting, other substance abuse, sexual risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/35/21050/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=see_link\">",
"       \"Patient information: Growth hormone treatment (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29409?source=see_link\">",
"       \"Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of androgens, growth hormone, and other drugs to improve athletic performance is common, even in adolescents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all androgens produced for human or veterinary purposes have been taken by athletes (",
"      <a class=\"graphic graphic_figure graphicRef53955 \" href=\"UTD.htm?15/21/15699\">",
"       figure 1",
"      </a>",
"      ). These include testosterone esters, which are usually taken by injection, the 17-alpha-alkylated androgens, which are usually taken orally, androgen precursors, and possibly selective androgen receptor modulators. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Androgens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exogenous testosterone administration increases serum testosterone concentrations, fat-free mass, and muscle strength. There is no evidence that androstenedione increases muscle strength. The evidence for DHEA is equivocal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of androgen use include suppression of endogenous testicular function, gynecomastia, erythrocytosis, hepatotoxicity (with 17-alpha-akylated androgens), psychological disorders, a decrease in serum HDL (especially with 17-alpha-akylated androgens), coagulation activation, premature epiphyseal fusion (in adolescents), infections, and virilization (in women). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of androgens for nonmedical purposes is associated with risky behavior, such as smoking and alcohol abuse, and violent behavior, but no causal relationship has been demonstrated. (See",
"      <a class=\"local\" href=\"#H606911092\">",
"       'Neuropsychiatric'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of androgen use by athletes is difficult. The conventional method used is the urinary ratio of testosterone glucuronide to its endogenous epimer, epitestosterone glucuronide",
"      <span class=\"nowrap\">",
"       (T/E",
"      </span>",
"      ratio). Normally, the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio is 1 to 3:1; a",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio of &gt;4:1 is considered evidence of doping by the World Anti-Doping Agency (WADA). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Detection of use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The utility of the",
"      <span class=\"nowrap\">",
"       T/E",
"      </span>",
"      ratio is limited by its significant between subject variability, due to genetically determined differences in the ability to convert testosterone to testosterone glucuronide. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Detection of use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A man who wishes to stop should be encouraged to do so but warned that he will become hypogonadal for up to several months before he recovers endogenous testicular function. hCG should not be prescribed because it has not been shown to speed this process and because some men say they want to stop taking androgens as an excuse to get a prescription for hCG.",
"     </li>",
"     <li>",
"      Human growth hormone is also commonly used to enhance athletic performance. Clinical trial data suggest that while lean body mass may be increased by growth hormone use, strength and exercise capacity is not. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Growth hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of exogenous growth hormone use by athletes is difficult. There are two approaches currently being used: measurement of markers of growth hormone action (IGF-I and N-terminal extension peptide of procollagen type III [P-III-P]), and measurement of growth hormone isoforms that can distinguish exogenous growth hormone from rhGH. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Growth hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythropoietin increases the blood&rsquo;s maximum capacity to transport and utilize oxygen, thereby augmenting aerobic power and physical exercise tolerance. Major adverse effects of erythropoietin include myocardial infarction, stroke, and thromboembolic disease. (See",
"      <a class=\"local\" href=\"#H1353819\">",
"       'Erythropoiesis-stimulating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other banned substances and dietary supplements that are often used by athletes include stimulants, insulin, and beta blockers. Creatine is not currently on the list of banned substances of any governing bodies, but the NCAA prohibits its distribution to athletes by its member institutions. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/1\">",
"      Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA 1996; 276:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/2\">",
"      Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/3\">",
"      Sj&ouml;qvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/4\">",
"      Melnik BC. Androgen abuse in the community. Curr Opin Endocrinol Diabetes Obes 2009; 16:218.",
"     </a>",
"    </li>",
"    <li>",
"     United States Anti-Doping Agency - Results Management. file://www.usada.org/results/ (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/6\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     Monitoring the Future - a continuing study of American youth. file://www.monitoringthefuture.org (Accessed on February 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/8\">",
"      Holt RI, S&ouml;nksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol 2008; 154:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/9\">",
"      Buckman JF, Yusko DA, White HR, Pandina RJ. Risk profile of male college athletes who use performance-enhancing substances. J Stud Alcohol Drugs 2009; 70:919.",
"     </a>",
"    </li>",
"    <li>",
"     United States Anti-Doping Agency - Substances. file://www.usada.org/substances (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     The World Anti-Doping Agency. Available at: www.wada-ama.org (Accessed on February 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/12\">",
"      HERSHBERGER LG, SHIPLEY EG, MEYER RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/13\">",
"      Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/14\">",
"      Darimont BD, Wagner RL, Apriletti JW, et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 1998; 12:3343.",
"     </a>",
"    </li>",
"    <li>",
"     The Federal Register - US Department of Justice, Drug Enforcement Administration. Rules regarding the implementation of the Anabolic Steroid Control Act of 2004. file://www.thefederalregister.com/d.p/2005-12-16-05-23907 (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/16\">",
"      Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/17\">",
"      King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999; 281:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/18\">",
"      Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000; 85:4074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/19\">",
"      Acacio BD, Stanczyk FZ, Mullin P, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril 2004; 81:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/20\">",
"      Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 1999; 31:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/21\">",
"      Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/22\">",
"      Kohler M, Thomas A, Geyer H, et al. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test Anal 2010; 2:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/23\">",
"      Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006; 23:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/24\">",
"      Handelsman DJ. Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab 2006; 91:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/25\">",
"      Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/26\">",
"      Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/27\">",
"      Broeder CE, Quindry J, Brittingham K, et al. The Andro Project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000; 160:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/28\">",
"      Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 1989; 52:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/29\">",
"      Gazvani MR, Buckett W, Luckas MJ, et al. Conservative management of azoospermia following steroid abuse. Hum Reprod 1997; 12:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/30\">",
"      Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998; 111:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/31\">",
"      Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/32\">",
"      Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart 2004; 90:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/33\">",
"      Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/34\">",
"      Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/35\">",
"      Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/36\">",
"      Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/37\">",
"      O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav 2002; 75:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/38\">",
"      Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/39\">",
"      Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000; 57:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/40\">",
"      McCabe SE, Brower KJ, West BT, et al. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend 2007; 90:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/41\">",
"      Beaver KM, Vaughn MG, Delisi M, Wright JP. Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States. Am J Public Health 2008; 98:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/42\">",
"      Gruber AJ, Pope HG Jr. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom 2000; 69:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/43\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 484: Performance enhancing anabolic steroid abuse in women. Obstet Gynecol 2011; 117:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/44\">",
"      Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/45\">",
"      Stergiopoulos K, Brennan JJ, Mathews R, et al. Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. Vasc Health Risk Manag 2008; 4:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/46\">",
"      Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend 2002; 65:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/47\">",
"      Fern&aacute;ndez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/48\">",
"      Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elbow Surg 1998; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/49\">",
"      Cope MR, Ali A, Bayliss NC. Biceps rupture in body builders: three case reports of rupture of the long head of the biceps at the tendon-labrum junction. J Shoulder Elbow Surg 2004; 13:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/50\">",
"      Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/51\">",
"      Catlin DH, Cowan DA. Detecting testosterone administration. Clin Chem 1992; 38:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/52\">",
"      Sottas PE, Saudan C, Schweizer C, et al. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci Int 2008; 174:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/53\">",
"      Schulze JJ, Lundmark J, Garle M, et al. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/54\">",
"      Jakobsson J, Ekstr&ouml;m L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/55\">",
"      Schulze JJ, Lorentzon M, Ohlsson C, et al. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenet Genomics 2008; 18:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/56\">",
"      Stenman UH, Hotakainen K, Alfthan H. Gonadotropins in doping: pharmacological basis and detection of illicit use. Br J Pharmacol 2008; 154:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/57\">",
"      Aguilera R, Chapman TE, Starcevic B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/58\">",
"      Thevis M, Kohler M, Sch&auml;nzer W. New drugs and methods of doping and manipulation. Drug Discov Today 2008; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/59\">",
"      Thomas A, Kohler M, Sch&auml;nzer W, et al. Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/60\">",
"      Malvey TC, Armsey TD 2nd. Tetrahydrogestrinone: the discovery of a designer steroid. Curr Sports Med Rep 2005; 4:227.",
"     </a>",
"    </li>",
"    <li>",
"     United States Anti-Doping Agency - Therapeutic Use Exemptions (TUE). file://www.usada.org/tue/ (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/62\">",
"      Handelsman DJ. Indirect androgen doping by oestrogen blockade in sports. Br J Pharmacol 2008; 154:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/63\">",
"      Mareck U, Geyer H, Guddat S, et al. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/64\">",
"      Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med 2007; 28:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/65\">",
"      Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008; 148:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/66\">",
"      Deyssig R, Frisch H, Blum WF, Waldh&ouml;r T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh) 1993; 128:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/67\">",
"      Yarasheski KE, Campbell JA, Smith K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992; 262:E261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/68\">",
"      Berggren A, Ehrnborg C, Ros&eacute;n T, et al. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab 2005; 90:3268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/69\">",
"      Meinhardt U, Nelson AE, Hansen JL, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med 2010; 152:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/70\">",
"      Fernandez MM, Hosey RG. Performance-enhancing drugs snare nonathletes, too. J Fam Pract 2009; 58:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/71\">",
"      Segura J, Guti&eacute;rrez-Gallego R, Ventura R, et al. Growth hormone in sport: beyond Beijing 2008. Ther Drug Monit 2009; 31:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/72\">",
"      Brennan BP, Kanayama G, Hudson JI, Pope HG Jr. Human growth hormone abuse in male weightlifters. Am J Addict 2011; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/73\">",
"      Bidlingmaier M, Strasburger CJ. Technology insight: detecting growth hormone abuse in athletes. Nat Clin Pract Endocrinol Metab 2007; 3:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/74\">",
"      Powrie JK, Bassett EE, Rosen T, et al. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007; 17:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/75\">",
"      Nelson AE, Meinhardt U, Hansen JL, et al. Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab 2008; 93:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/76\">",
"      Travis J. Pharmacology. Growth hormone test finally nabs first doper. Science 2010; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/77\">",
"      Rich JD, Dickinson BP, Merriman NA, Thule PM. Insulin use by bodybuilders. JAMA 1998; 279:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/78\">",
"      Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol 2008; 154:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/79\">",
"      Spedding M, Spedding C. Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry. Br J Pharmacol 2008; 154:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/80\">",
"      Prommer N, Sottas PE, Schoch C, et al. Total hemoglobin mass--a new parameter to detect blood doping? Med Sci Sports Exerc 2008; 40:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/81\">",
"      Lamon S, Robinson N, Sottas PE, et al. Possible origins of undetectable EPO in urine samples. Clin Chim Acta 2007; 385:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/82\">",
"      Orchard JW, Fricker PA, White SL, et al. 4. The use and misuse of performance-enhancing substances in sport. Med J Aust 2006; 184:132.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd, Lippincott Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/35/21050/abstract/84\">",
"      Miller KE, Hoffman JH, Barnes GM, et al. Adolescent anabolic steroid use, gender, physical activity, and other problem behaviors*. Subst Use Misuse 2005; 40:1637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7475 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21050=[""].join("\n");
var outline_f20_35_21050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606912358\">",
"      Patterns of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606912732\">",
"      Banned drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANDROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types of androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606909518\">",
"      - Exogenous testosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606909511\">",
"      - Synthetic androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Androgen precursors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606910564\">",
"      - SARMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606909468\">",
"      - Other forms of androgen stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H606911831\">",
"      Use of hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606911486\">",
"      - Reproductive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606911084\">",
"      - Cardiac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606914355\">",
"      - Lipids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606914362\">",
"      - Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606911092\">",
"      - Neuropsychiatric",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H273222414\">",
"      - Prostate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H493467\">",
"      - Tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Detection of use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606909324\">",
"      - Testosterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606909380\">",
"      - Other androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606910879\">",
"      - hCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606912472\">",
"      Avoiding detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606909303\">",
"      Therapeutic use exemption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606910333\">",
"      ESTROGEN BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4121017\">",
"      Antiestrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606910666\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GROWTH HORMONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606911755\">",
"      Physical effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606911809\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606911629\">",
"      Detection methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606910688\">",
"      Growth factors: IGF-I and insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1353812\">",
"      METHODS TO INCREASE OXYGEN TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1353819\">",
"      Erythropoiesis-stimulating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1415409\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76826127\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76825861\">",
"      Detection methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606911964\">",
"      CONSEQUENCES OF USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606912021\">",
"      Stopping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12224280\">",
"      ROUTINE SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7475|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/21/15699\" title=\"figure 1\">",
"      Testosterone preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/21/4447\" title=\"figure 2\">",
"      Genotype urine excretion T",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/46/13025\" title=\"table 1\">",
"      The 2010 Prohibited List",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=related_link\">",
"      Management of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/19/9529?source=related_link\">",
"      Non-hormonal performance enhancement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29409?source=related_link\">",
"      Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=related_link\">",
"      Patient information: Growth hormone treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_35_21051="Viral cause common cold";
var content_f20_35_21051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Viral cause of the common cold",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Virus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated annual proportion of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhinoviruses",
"       </td>",
"       <td>",
"        30-50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronaviruses",
"       </td>",
"       <td>",
"        10-15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza viruses",
"       </td>",
"       <td>",
"        5-15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory syncytial virus",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parainfluenza viruses",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenoviruses",
"       </td>",
"       <td>",
"        &lt;5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroviruses",
"       </td>",
"       <td>",
"        &lt;5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metapneumovirus",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        20-30 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Heikkinen T, Jarvinen A. The common cold. Lancet 2003; 361:51. Copyright &copy;2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21051=[""].join("\n");
var outline_f20_35_21051=null;
var title_f20_35_21052="Elbow examination findings and diagnosis";
var content_f20_35_21052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examination of the elbow: Findings and diagnosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Examination signs",
"      </td>",
"      <td class=\"subtitle1_single\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1_single\">",
"       Confirmation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tenderness of the lateral epicondyle*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       #1 - Lateral epicondylitis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Local anesthetic block at the lateral epicondyle (optional)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain reproduced by resisted wrist extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain reproduced by resisted radial deviation of the wrist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diminished grip strength",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tenderness of the medial epicondyle*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       #2 - Medial epicondylitis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Local anesthetic block at the medial epicondyle (optional)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain reproduced by resisted wrist flexion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain reproduced by resisted ulnar deviation of the wrist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diminished grip strength",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cystic swelling or thickening over the olecranon process*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Olecranon bursitis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Aspiration of the bursa for cell count, gram stain, and crystal analysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normal range of motion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of full elbow extension*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Radiohumeral arthritis",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Aspiration of the joint from the lateral approach",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lateral bulge sign half way between the lateral epicondyle and the olecranon process",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of full flexion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Loss of supination or pronation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain \"through\" the elbow*",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Referred pain from the neck or shoulder",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Screening neck and shoulder examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normal elbow range of motion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No local epicondylar tenderness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No olecranon swelling",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"     <br>",
"      #1 and #2 refer to the two most common conditions affecting the elbow.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21052=[""].join("\n");
var outline_f20_35_21052=null;
var title_f20_35_21053="Drugs and gynecomastia";
var content_f20_35_21053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with gynecomastia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\">",
"          Antiandrogens/inhibitors of androgen synthesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cyproterone acetate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Flutamide, bicalutamide, nilutamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Finasteride, dutasteride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Spironolactone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ketoconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          PC-SPECS (OTC herbal)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lavender oil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tea tree oil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"          Antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethionamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ketoconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metronidazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\">",
"          Antiulcer drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ranitidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Omeprazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\">",
"          Cancer chemotherapeutic drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alkylating agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methotrexate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vinca alkaloids",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Combination chemotherapy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Imatinib",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cardiovascular drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ACE inhibitors: captopril, enalapril",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Calcium channel blockers: diltiazem, nifedipine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Digitoxin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methyldopa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Reserpine",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Drugs of abuse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alcohol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amphetamines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Heroin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Marijuana",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"1\" rowspan=\"1\">",
"          Methadone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Hormones",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Androgens",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anabolic steroids",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chorionic gonadotropin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Estrogens",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Growth hormone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\">",
"          Psychoactive drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diazepam",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Haloperidol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenothiazines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tricyclic antidepressants",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\" colspan=\"1\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Auranofin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diethylproprion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Domperidone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Etretinate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          HAART therapy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metoclopramide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenytoin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Penicillamine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulindac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Theophylline",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The association between many of the drugs listed and gynecomastia is based on case reports, and, therefore, may not represent a true cause-and-effect relationship.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21053=[""].join("\n");
var outline_f20_35_21053=null;
var title_f20_35_21054="CK levels post PTCA outcome";
var content_f20_35_21054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Elevated serum CK-MB is associated with cardiac events after angioplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After percutaneous transluminal coronary angioplasty (PTCA), the six-month incidence of cardiac events including death, myocardial infarction (MI), or revascularization with bypass surgery (CABG) or repeat PTCA was directly associated with the serum CK-MB. Shown are point estimates and 95 percent confidence intervals by postintervention CK-MB stratum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tardiff BE, Califf RM, Tcheng JE, et al. J Am Coll Cardiol 1999; 33:88.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21054=[""].join("\n");
var outline_f20_35_21054=null;
var title_f20_35_21055="Lupus vulgaris histopathology";
var content_f20_35_21055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperkeratosis, pseudoepitheliomatous hyperplasia, and tuberculoid granulomas are evident in this specimen from a lesion of lupus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Ma. Flordeliz Abad-Casintahan.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_35_21055=[""].join("\n");
var outline_f20_35_21055=null;
